

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representation of
The original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**

THIS PAGE BLANK (USPTO)

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
1 May 2003 (01.05.2003)

PCT

(10) International Publication Number
WO 03/034820 A1

(51) International Patent Classification⁷: **A01N 1/02,**
63/00, C12N 5/08

European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(21) International Application Number: PCT/US02/29591

(22) International Filing Date:
17 September 2002 (17.09.2002)

Declarations under Rule 4.17:

— as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) for the following designations AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
09/957,194 19 September 2001 (19.09.2001) US
10/071,016 7 February 2002 (07.02.2002) US

— as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) for the following designations AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)

(71) Applicant: **MEDCELL BIOLOGICS, LLC.** [US/US];
17140 Bernardo Center Drive, Suite 150, San Diego, CA
92128 (US).

(72) Inventors: **GRUENBERG, Micheal, L.**; 14665 Deer-
wood Street, Poway, CA 92064-5248 (US). **CHAVAN,**
Surendra; 11289 Paseo Montanso, San Diego, CA 92127
(US).

(74) Agents: **SEIDMAN, Stephanie, L.** et al.; Heller Ehrman
White & McAuliffe LLP, 4350 La Jolla Village Drive, 7th
floor, San Diego, CA 92122-1246 (US).

(81) Designated States (national): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,
MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG,
SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC,
VN, YU, ZA, ZM, ZW.

Published:

— with international search report

(84) Designated States (regional): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: Th1 CELL ADOPTIVE IMMUNOTHERAPY

(57) Abstract: Methods for consistently producing a pure population of activated, polyclonal, Th1 memory cells for use in adoptive immunotherapy without the use of any exogenous cytokines and without significant subject-to-subject variation are provided. The resulting cells obtain a surface phenotype that enables their trafficking to tumors and other sites of inflammation upon infusion. The cells can be reinfused into the a subject to enhance the cellular immune response and/or switch the predominant immune response from Th2-dominated to a Th1-dominated immune response.



WO 03/034820 A1

-1-

Th1 CELL ADOPTIVE IMMUNOTHERAPY**RELATED APPLICATIONS**

Benefit of priority to U.S. application Serial No. 10/071,016, filed February 7, 2002, to Micheal Gruenberg, entitled "Th1 CELL ADOPTIVE IMMUNOTHERAPY", and U.S. application Serial No. 09/957,194, filed September 19, 2001, to Micheal Gruenberg, entitled "Th1 CELL ADOPTIVE IMMUNOTHERAPY" is claimed. Where permitted, the subject matter of each of these applications is incorporated by reference in its entirety.

10 This application is related to U.S. application Serial No. 08/506,668, converted to U.S. provisional application Serial No. 60/044,693, now abandoned; pending U.S. applications Serial Nos. 08/700,565, 09/127,411, 09/127,142, 09/127,138, 09/127,141 and 09/824,906, International PCT application No. WO 97/05239, U.S. provisional application Serial No. 60/322,626, filed September 17, 2001, 15 U.S. application Serial No. (attorney Docket No. 24731-504C), filed the same day herewith, and U.S. application Serial No. 10/094,667. Where permitted, the subject matter of each of these applications is incorporated by reference in its entirety.

20 FIELD OF THE INVENTION

This invention relates to immunotherapy. In particular, methods for the *ex vivo* production of autologous T-cells and the resulting T-cells for adoptive immunotherapy are provided.

BACKGROUND

25 The immune system is designed to eradicate a large number of pathogens, as well as tumors, with minimal immunopathology. When the immune system becomes defective, however, numerous disease states result. Immunotherapy is an emerging treatment modality that seeks to harness the power of the human immune system to treat disease.

-2-

Immunotherapy seeks to enhance the cellular immune response in diseases characterized by immunosuppression and suppress the cellular immune response in subjects with diseases characterized by an overactive cellular immune response.

- 5 One immunotherapy method for enhancing the cellular immune response in subjects is a type of cell therapy called adoptive immunotherapy. A cell therapy is a drug whose active ingredient is wholly or in part a living cell. Adoptive immunotherapy is a cell therapy that involves the removal of immune cells from a subject, the ex-vivo
10 processing (i.e., activation, purification and/or expansion of the cells) and the subsequent infusion of the resulting cells back into the same subject.

- Examples of adoptive immunotherapy methods include methods for producing and using LAK cells (Rosenberg U.S. Patent No. 4,690,915), TIL cells (Rosenberg U.S. Patent No. 5,126,132), cytotoxic T-cells (Cai,
15 et al U.S. Patent No. 6,255,073; Celis, et al. U.S. Patent No. 5,846,827), expanded tumor draining lymph node cells (Terman U.S. Patent No. 6,251,385), various preparations of lymphocytes (Bell, et al US Pat No 6,194,207; Ochoa, et al. US Pat No 5,443,983; Riddell, et al. U.S. Patent No. 6,040,180; Babbitt, et al. U.S. Patent No. 5,766,920;
20 Bolton U.S. Patent No. 6,204,058), CD8 + TIL cells (Figlin *et al.* (1997) *Journal of Urology* 158:740), CD4 + T-cells activated with anti-CD3 monoclonal antibody in the presence of IL-2 (Nishimura (1992) *J. Immunol.* 148:285), T-cells co-activated with anti-CD3 and anti-CD28 in the presence of IL-2 (Garlie *et al.* (1999) *Journal of Immunotherapy*
25 22:336) antigen-specific CD8 + CTL T-cells produced ex-vivo and expanded with anti-CD3 and anti-CD28 monoclonal antibodies (mAb) in the presence of IL-2 (Oelke *et al.* (2000) *Clinical Cancer Research* 6:1997), and injection of irradiated autologous tumor cells admixed with Bacille Calmette-Guérin (BCG) to vaccinate subjects followed seven days

-3-

later by recovery of draining lymph node T-cells which are activated with anti-CD3 mAb followed by expansion in IL-2 (Chang *et al.* (1997) *Journal of Clinical Oncology* 15:796).

Adoptive immunotherapy once held great promise as a treatment method, but enthusiasm has since faded. Despite great efforts by academic and commercial laboratories, none of these prior adoptive immunotherapy methods have been approved by the Food and Drug Administration (FDA) as a therapy to treat human disease. There have been numerous obstacles in obtaining FDA approval for this type of treatment regimen. The most significant have been the infrequent and sporadic efficacy and high toxicity associated with these treatments. The reasons for the infrequent and sporadic efficacy of these treatments is not clearly understood, but may be related to the types, purity and dosages of cells used in the protocols, as well as subject-to-subject variations. The high toxicity is associated with the requirement that immune cells that have been processed ex-vivo be infused concomitantly with the highly toxic growth factor, interleukin-2 (IL-2), in order to maintain their viability and function.

Prior adoptive immunotherapy methods have focused on the differentiation and expansion of effector cells (e.g, LAK, NK and CTL). A new immunological paradigm has emerged that has taught the importance of regulatory cells, such as Th1 and Th2 cells, in the immune response. For the most part, current adoptive immunotherapy methods do not take advantage of this knowledge.

Functionally distinct regulatory cells, called Th1 and Th2, are found in both mice and in humans (Mosmann *et al* (1989) *Advances in Immunology* 46:111; Romagnani *et al* (1991) *Immunology Today* 12:256). The functional division of CD4+ lymphocytes into Th1 and Th2 subsets is based upon their cytokine profile. Th1 cells produce gamma

-4-

interferon (IFN- γ) and interleukin-2 (IL-2), but not IL-4. Th2 cells produce IL-4, but not IFN- γ (Mosmann *et al.* (1989) *Advances in Immunology* 46:111; Mosmann *et al.* (1989) *Annual Review of Immunology* 7:145; Mosmann *et al.* (1986) *Journal of Immunology* 136:2348; Fiorentino *et al.* (1989) *Journal of Experimental Medicine* 170:2081). Cytokines produced by these two subsets are mutually inhibitory and establish a reciprocal cross regulation. Th1 cells inhibit the proliferation of Th2 cells and Th2 cells inhibit Th1 cell cytokine production (Fiorentino *et al.* (1989) *Journal of Experimental Medicine* 170:2081). This cross regulation results in a polarized Th1 or Th2 immune response to pathogens that can determine either host resistance or susceptibility to infection. For example, a Th1 response in protozoan, viral or fungal infection is associated with resistance, while a Th2 response to these pathogens is associated with disease (Sher *et al.* (1992) *Immunological Reviews* 127:183; Scott *et al.* (1991) *Immunology Today* 12:346).

These observations have led to a new immunological paradigm. It is now widely believed that the homeostasis of the immune system is regulated by the balance of cytokines produced by Th1 and Th2 lymphocyte subsets (Tanaka *et al.* (1998) *Rinsho Byori Japanese Journal of Clinical Pathology* 46:1247), whereas imbalances in Th1/Th2 cytokines correlates with disease (Shurin *et al.* (1999) *Seminars in Immunopathology* 21:339).

Copending U.S. application Serial No. 08/506,668, converted to U.S. provisional application Serial No. 60/044,693, now abandoned; pending U.S. applications Serial Nos. 08/700,565, 09/127,411, 09/127,142, 09/127,138, 09/127,141, 09/824,906, and International application No. WO 97/05239 provide methods for ex-vivo T-cell expansion from subjects without the use of exogenous IL-2 and methods for producing compositions of T-cells, including Th1 cells, that are

-5-

predominately Th1 (greater than 50%) for the treatment of a variety of diseases. The methods described therein require the use of exogenous cytokines to cause the differentiation of Th1 cells. Further improvement of the methods described therein to consistently produce more

- 5 homogenous populations of Th1 cells without the use of exogenous cytokines and with a phenotype that would enable their trafficking to tumors and other sites of inflammation is desirable.

- There is a need to develop new methods for adoptive immunotherapy that permit consistent production of cell products that do
- 10 not vary subject-to-subject and do not require the use of exogenous cytokines or the concomitant infusion of toxic growth factors. There is also a need to develop new cell compositions that improve the efficacy associated with this therapeutic approach.

- Accordingly, among the objects herein, it is an object herein to
- 15 provide such methods. Also among the objects herein, it is an object herein to provide an immunotherapeutic technology that employs natural immunoregulatory mechanisms to stimulate an immune response.

SUMMARY

- Methods for consistently producing a population of highly pure,
- 20 cells that produce high quantities of gamma-interferon and negligible, if any, IL-4, are produced. The methods produce cells that are activated, polyclonal memory Th1 cells. In accord with the methods provided herein, these are produced from a subject blood sample in the absence of any exogenous growth or differentiation factors (such as IL-2 or IFN- γ).
- 25 The resulting cells can be used in adoptive immunotherapy protocols.

The cells produced by the methods can be used, for example, to enhance the cellular immune response or to switch a Th2-dominated immune response to a Th1-dominated immune response in subjects. These cells have therapeutic application in subjects suffering from a

-6-

variety of diseases, including cancer, infectious diseases, aging, allergic and other inflammatory diseases and diseases characterized by overactive humoral immunity (such as in systemic lupus erythematosus).

The methods provided herein include, some or all (as necessary), of
5 the steps of: (i) collecting source material from a subject; (ii) purifying T-cells from the source material; (iii) activating frequently (such as every 2-3 days) and repeatedly (a minimum of 3 times for the exemplified embodiment) the purified T-cells; and optionally (iv) reinfusing the resulting cells into the same subject or an allogeneic recipient.

10 The purification step minimizes the subject-to-subject variability of the cells resulting from the process. The frequent and repeated activation step causes the differentiation and expansion of a highly pure population of activated, polyclonal, memory Th1 cells. The methods do not require the addition of any exogenous growth or differentiation factors.

15 It is shown herein that frequent restimulation of T-cells or T-cell subsets with, for example, immobilized anti-CD3 and anti-CD28 mAb, causes them to proliferate and differentiate into a highly pure population of activated memory Th1 cells useful for adoptive immunotherapy of diseases characterized by either a lack of cellular immunity or an excess
20 of humoral immunity. The frequency of the restimulation must be every 2-3 days and the restimulation must be repeated typically 3 or 4 times in order to obtain a pure population of activated Th1 memory cells.

Activation with these antibodies more than 5 times, however, results in diminishing cytokine production and increased activation-induced cell
25 death.

The source material contains mononuclear cells collected from a blood sample, such as by leukapheresis or any suitable collection method. According to a method provided herein, a population of CD3+ T-cells is first purified from the source material. In an exemplary embodiment of

-7-

the method herein, the source material is first purified to obtain a starting population of CD4+ T-cells. The CD4+ cells are purified, for example, by positive selection techniques. In another exemplary embodiment, the purified CD4+ T-cells are purged of CD45RO+ memory cells resulting in
5 a starting population of CD4+, CD45RA+ naïve T-cells (pTh cells).

The starting population of T-cells (either CD3+ or CD4+ or CD4, CD45RA+) are next frequently and repeatedly activated. In one embodiment, the cells are activated by simultaneous contact with a first agent that stimulates the TCR/CD3 complex of the T-cells and a second
10 agent which stimulates the CD28 receptor complex. In another exemplary embodiment, the activation is accomplished by co-incubating the starting population of T-cells with immunomagnetic beads conjugated with anti-CD3 and anti-CD28 monoclonal antibodies. In another embodiment, the beads are colloidal size particles.

15 The frequent and repeated re-activation causes the cells to expand and differentiate. In order to cause Th1 memory differentiation, the T-cells must be activated at least 3 times, typically 4 times, every 2-4 days, generally every 3 days. In an exemplary embodiment, the T-cells are activated 2 to 4 times with anti-CD3/anti-CD28-conjugated
20 immunomagnetic beads every 3 days.

In another exemplary embodiment, the cells are activated two to four times with anti-CD3/anti-CD28-conjugated colloidal beads. The colloidal beads result in cells that produce higher levels of cytokines, such as gamma-interferon, that are typical of Th1 cells. In particular,
25 cells are activated a plurality of times with anti-CD3/anti-CD28-conjugated microbeads beads (Milenyi Biotec, Auburn CA; see, U.S. Patent No. 6,417,011), which are colloidal size dextran coated paramagnetic beads. Repeated activation with the microbeads results in higher production of Th1 cells than re-activation with the

-8-

immunomagnetic beads. In addition, these beads offer an advantage that they are absorbed by the cells and do not have to be removed from the cultured cells.

The frequent and repeated activation results in cells that expand in excess of 100-fold in the absence of exogenous growth factors, such as IL-2. In order to consistently expand cells from subjects with cancer without the use of exogenous cytokines, the source material must be first purged of platelets. The platelets from cancer subjects are a source of TGF-beta, which inhibits the expansion of T-cells. In other embodiments, the source material is purged of monocytes prior to purification of CD4 + T-cells by positive selection.

Compositions containing the cells resulting from the method are provided. These cells can be used, for example, to treat cancers, infectious diseases, allergic diseases and suppress the humoral immune response in diseases characterized by overactive humoral immunity. The cells resulting from the method have a unique phenotype: CD3 +, CD45RO +, CD25 +, CD40L +, CD62L-, CD44 +. The cells internally stain positive for IFN- γ and do not produce IL-4. The cells produce proinflammatory Th1 cytokines, including IFN- γ , TNF-alpha and IL-2. Cells of this phenotype, referred to herein as activated, polyclonal memory Th1 cells, have the ability to leave the vasculature upon reinfusion and enter cancerous lesions and other sites of inflammation. The compositions typically contain at least about 10^8 , 10^9 , 10^{10} , 10^{11} , 10^{12} and more cells, generally contained in a volume of a liter or less.

The capability to deliver proinflammatory Th1 cytokines within tumors and sites of inflammation can shift a resident immune response from a Th2-dominated response to a Th1-dominated immune response. Th1 cytokines also have a proven ability to act as a general booster of the cellular immune response. This is a unique mechanism of action for cells

-9-

used in adoptive immunotherapy and will be beneficial to subjects suffering from various forms of cancer, infectious diseases and allergic diseases, and other diseases characterized by either suppressed cellular immunity or enhanced humoral immunity.

- 5 The method consistently produces high purity activated, polyclonal memory Th1 cells without any exogenous cytokines, such as IL-2, and without significant subject-to-subject variation. This permits the cells to be infused without the concomitant infusion of IL-2. The consistent production of a pure cell product combined with the unique mechanism of
10 action and lack of toxic cytokines is an improvement over prior adoptive immunotherapy methods and will result in an improved therapeutic index.

- The method also can enhance the activated, Th1 memory cell component of a population of cells that result when the source cells are CD3+, CD4+, CD45RO+ memory cells. Such enhancement occurs
15 even in memory cells derived from a subject with a Th2-dominated disease, such as a cancer subject. The method herein, which relies on repeated and frequent activation, causes the endogenous production of large amounts of IFN- γ , which inhibits Th2 cytokine production. The method also preferentially expands Th1 cells. Thus, even a starting Th2
20 cell-enriched population, such as CD4+, CD45RO+ memory cells from cancer subjects, when treated in accord with the methods herein, produces a population that is enhanced in Th1 memory cells.

- Also provided herein vaccines that are a combination of the cells produced herein and an immunizing antigen, and methods of vaccinating
25 by co-infusing, either sequentially or simultaneously, the cells produced herein and an immunizing antigen. Immunizing antigens include but are not limited to, tumor-associated antigens, viral antigens bacterial antigens and other antigens against which an immunoprotective or disease-ameliorative response is desired.

-10-

Methods of treatment of diseases characterized by suppression of the cellular immune response or by over-expression of the humoral immune response are provided. Such diseases include, but are not limited to, cancer, infectious diseases, autoimmune, inflammatory
5 response, allergic diseases and aging. Included among the cancers are liver, kidney, breast, prostate, melanoma, colon, lymphoma, lung, pancreatic, ovarian, esophageal, head and neck, brain, uterine, stomach and other cancers.

The cells produced by each of the methods provided herein are
10 administered to the donor of the cells or to an allogenic recipient. A sufficient number of cells are administered to ameliorate the symptoms of the disease. Typically at least about 10^8 - 10^{11} cells, generally at least about 10^9 cells are administered either as a single dosage or in several dosages.

15 DETAILED DESCRIPTION

A. Definitions

Unless defined otherwise, all technical and scientific terms used herein have the same meaning as is commonly understood by one of skill in the art to which the invention(s) belong. All patents, patent
20 applications, published applications and publications, Genbank sequences, websites and other published materials referred to throughout the entire disclosure herein, unless noted otherwise, are incorporated by reference in their entirety. In the event that there are a plurality of definitions for terms herein, those in this section prevail. Where reference is made to a
25 URL or other such identifier or address, it is understood that such identifiers can change and particular information on the internet can come and go, but equivalent information can be found by searching the internet. Reference thereto evidences the availability and public dissemination of such information.

-11-

As used herein, cell therapy is a method of treatment involving the administration of live cells. Adoptive immunotherapy is a treatment process involving removal of cells from a subject, the processing of the cells in some manner ex-vivo and the infusion of the processed cells into
5 the same subject as a therapy.

As used herein, source material is the population of cells that are collected from a subject for further processing into an adoptive immunotherapy. Source material generally is mononuclear cells collected, for example, by leukapheresis.

10 As used herein, immune cells are the subset of blood cells known as white blood cells, which include mononuclear cells such as lymphocytes, monocytes, macrophages and granulocytes.

As used herein, T-cells are lymphocytes that express the CD3 antigen.

15 As used herein, helper cells are CD4 + lymphocytes.

As used herein, regulatory cells are a subset of T-cells, most commonly CD4 + T-cells, that are capable of enhancing or suppressing an immune response. Regulatory immune cells regulate an immune response primarily by virtue of their cytokine secretion profile. Some regulatory
20 immune cells can also act to enhance or suppress an immune response by virtue of antigens expressed on their cell surface and mediate their effects through cell-to-cell contact. Th1 and Th2 cells are examples of regulatory cells.

As used herein, effector cells are immune cells that primarily act to
25 eliminate tumors or pathogens through direct interaction, such as phagocytosis, perforin and/or granzyme secretion, induction of apoptosis, and other such processes. Effector cells generally require the support of regulatory cells to function and are the mediators of delayed type hypersensitivity reactions and cytotoxic functions. Examples of

-12-

effector cells are B lymphocytes, macrophages, cytotoxic lymphocytes, LAK cells, NK cells and neutrophils.

As used herein, an activated cell is a T-cell that expresses CD25. Cells that express the IL-2 receptor (CD25) are referred to herein as
5 "activated". A pure or highly pure population of activated cells typically express greater than 85% positive for CD25.

As used herein, T-cells that produce IFN- γ , and not IL-4 upon stimulation are referred to as Th1 cells. Cells that produce IL-4, and not IFN- γ , are referred to as Th2 cells. A method for identifying Th1 cells in a
10 population of cells is to stain the cells internally for IFN- γ . Th2 cells are commonly identified by internal staining for IL-4. Normal (*i.e.*, subjects not exhibiting overt disease) individuals generally only about 12 -16% of the CD4+ cells stain positive for internal IFN- γ after activation; less than 1% stain positive for IFN- γ prior to activation. It is rare for a T-cell
15 population to stain greater than 35% IFN- γ positive. The cells resulting from the method stain greater than 70% positive and often greater than 90% positive for IFN- γ .

As used herein, a pure or highly pure population of Th1 cells is a population that stains greater than 70% positive for internal interferon- γ
20 and does not produce greater than about 26 pg/ml/ 10^6 cells of IL-4 in a 24 hour period. In most instances, they do not produce greater than about 6 pg/ml/ 10^6 cells of IL-4 in a 24 hour period.

As used herein, a memory cell is a T-cell that expresses CD45RO and not CD45RA. A pure or highly pure population of memory cells
25 expresses greater than 70%, generally greater than 80%, and even greater than 90% or 95% positive for CD45RO.

As used herein, a cell that has the ability to traffic to a tumor or other site of inflammation upon infusion, is a T-cell with an activated (CD25+) memory (CD45RO+) phenotype that expresses adhesion

-13-

molecules, such as CD44 and does not express CD62L. A pure or highly pure population of memory cells with the ability to traffic to a tumor or other site of inflammation upon infusion is greater than 70%, generally greater than 90% or 95% positive for CD44, and less than
5 about 25%, including less than 5%, positive for CD62L.

As used herein, activating proteins are molecules that when contacted with a T-cell population cause the cells to proliferate. Reference to activating proteins thus encompasses the combination of proteins that provide the requisite signals, which include an initial priming
10 signal and a second co-stimulatory signal. The first signal requires a single agent, such as anti-CD3 monoclonal antibody (mAb), anti-CD2 mAb, anti-TCR mAb, PHA, PMA, and other such signals. The second signal requires one or more agents, such as anti-CD28 mAb, anti-CD40L mAb, cytokines, feeder cells or other such signals. Thus activating
15 proteins include combinations of molecules including, but are not limited to: cell surface protein specific mAbs, fusion proteins containing ligands for a cell surface protein, or any molecule that specifically interacts with a cell surface receptor on a T-cell and directly or indirectly causes that cell to proliferate.

20 As used herein, a mitogenic mAb is an activating protein that is a monoclonal antibody specific for a T-cell surface expressed protein that when contacted with a cell directly or indirectly provides one of the at least two requisite signals for T-cell mitogenesis. Suitable mitogenic mAbs induce T-cell doubling times of 24 h to 48 h.

25 As used herein, a cytokine is a factor produced from a cell that has biological activity. A lymphokine is a cytokine produced by lymphocytes. Interleukins and interferons are examples of lymphokines.

As used herein, exogenous cytokines, refer to cytokines that are added to a sample or cell preparation. They do not include cytokines

-14-

produced by the cells in a sample or cell preparation *in vitro*, *in vivo* or *ex vivo*. Hence preparing cells in the absence of exogenous cytokines, refers to preparation without adding additional cytokines to those produced by the cells.

- 5 As used herein, a composition containing a clinically relevant number or population of immune cells is a composition that contains at least 10^9 , typically greater than 10^9 , at least 10^{10} cells, and generally more than 10^{10} cells. The number of cells will depend upon the ultimate use for which the composition is intended as will the type of cell. For
- 10 example, if Th1 cells that are specific for a particular antigen are desired, then the population will contain greater than 70%, generally greater than 80%, 85% and 90-95% of such cells. For uses provided herein, the cells are generally in a volume of a liter or less, can be 500 mls or less, even 250 mls or 100 mls or less. Hence the density of the desired cells
- 15 is typically be greater than 10^6 cells/ml and generally is greater than 10^7 cells/ml. The clinically relevant number of immune cells can be apportioned into multiple infusions that cumulatively equal or exceed 10^9 , 10^{10} or 10^{11} cells.

- As used herein, a clinically relevant number of activated polyclonal
- 20 Th1 memory cells is a composition containing a clinically relevant number or population of immune cells where a substantial portion, greater than at least about 70%, typically more than 80%, 90%, and 95%, of the immune cells are activated polyclonal Th1 memory cells.

- As used herein, polyclonal means cells derived from two or more
- 25 cells of different ancestry or genetic constitution. A polyclonal T-cell population is a population of T-cells that express a mixture of T cell receptor genes with no one T cell receptor gene dominating the population of cells.

 As used herein, predominant means greater than about 50%.

-15-

- As used herein, highly pure means greater than about 70%, generally greater than 75% and can be as pure as 85%, 90% or 95% or higher in purity. A highly pure population of Th1 cells, as used herein, is typically a population of greater than 95% CD3+, CD4+ T-cells that
- 5 stain greater than about 70% positive for internal IFN- γ and do not produce detectable amounts of IL-4 when assayed by ELISA (i.e., less than 26 pg/ml/ 10^6 cells). Internal staining for IL-4 is generally below 10% and most often below 5%. Occasionally higher numbers are observed. This is often an artifact of the detection technique, as cells that die by
- 10 apoptosis will stain positive for internal IL-4. Measurement of secretion into supernatants controls for this artifact. The amount of IFN- γ detected by ELISA is generally in excess of 1 ng/ml/ 10^6 cells and in the range of 1 ng/ml to 26 ng/ml per 10^6 cells, but can be greater than 26 ng/ml per 10^6 cells.
- 15 As used herein, a combination refers to two component items, such as compositions or mixtures, that are intended for use either together or sequentially. The combination may be provided as a mixture of the components or as separate components packaged or provided together, such as in a kit.
- 20 As used herein, colloidal size beads are particles of a size that form a colloid upon mixing with a liquid, such as an aqueous composition. Such particles typically have an a size where the largest dimension is about 0.01 to 2 microns. For purposes herein, it refers to the size of the particles produced in the method of Example 1G.
- 25 As used herein, effector cells are mononuclear cells that have the ability to directly eliminate pathogens or tumor cells. Such cells include, but are not limited to, LAK cells, MAK cells and other mononuclear phagocytes, TILs, CTLs and antibody-producing B cells and other such cells.

-16-

As used herein, immune balance refers to the normal ratios, and absolute numbers, of various immune cells and their cytokines that are associated with a disease free state. Restoration of immune balance refers to restoration to a condition in which treatment of the disease or disorder is effected whereby the ratios of regulatory immune cell types or their cytokines and numbers or amounts thereof are within normal range or close enough thereto so that symptoms of the treated disease or disorder are ameliorated. The amount of cells to administer can be determined empirically, or, such as by administering aliquots of cells to a subject until the symptoms of the disease or disorder are reduced or eliminated. Generally a first dosage will be at least 10^9 - 10^{10} cells. In addition, the dosage will vary depending upon treatment sought. As intended herein, about 10^9 is from about 5×10^8 up to about 5×10^9 ; similarly about 10^{10} is from about 5×10^9 up to about 5×10^{10} , and so on for each order of magnitude. Dosages refer to the amounts administered in one or in several infusions.

As used herein, therapeutically effective refers to an amount of cells that is sufficient to ameliorate, or in some manner reduce the symptoms associated with a disease. When used with reference to a method, the method is sufficiently effective to ameliorate, or in some manner reduce the symptoms associated with a disease.

As used herein, a subject is a mammal, typically a human, including patients.

As used herein, mononuclear or lymphoid cells (the terms are used interchangeably) include lymphocytes, macrophages, and monocytes that are derived from any tissue or body fluid in which such cells are present. In general lymphoid cells are removed from an individual who is to be treated. The lymphoid cells may be derived from a tumor, peripheral

-17-

blood, or other tissues, such as the lymph nodes and spleen that contain or produce lymphoid cells.

As used herein, a therapeutically effective number is a clinically relevant number of immune cells that is at least sufficient to achieve a
5 desired therapeutic effect, when such cells are used in a particular method. Typically such number is at least 10^8 , and generally 10^{10} or more. The precise number will depend upon the cell type and also the intended target or result and can be determined empirically.

As used herein, tissue culture medium includes any culture medium
10 that is suitable for the growth of mammalian cells *ex vivo*. Examples of such medium include, but are not limited to X-VIVO-15 (Biowhittaker) AIM-V, RPMI 1640, and Iscove's medium (GIBCO, Grand Island, N.Y.). The medium may be supplemented with additional ingredients including
15 substances, such mitogenic monoclonal antibodies and selective agents for selecting genetically engineered or modified cells.

As used herein, a disease characterized by a lack of Th1 cytokine activity refers to a state, disease or condition where the algebraic sum of cytokines in a specific microenvironment in the body or in a lesion(s) or
20 systemically is less than the amount of Th1 cytokines present normally found in such microenvironment or systemically (*i.e.*, in the subject or another such subject prior to onset of such state, disease or condition). The cytokines to assess include IFN- γ , IL-2, and TNF- α . The precise
25 amounts and cytokines to assess depend upon the particular state, disease or condition. Thus, the diseases for which the cells have therapeutic application include, but are not limited to, cancer, infectious diseases, allergic diseases and diseases characterized by overactive humoral immunity (such as in systemic lupus erythematosus).

-18-

As used herein, diseases characterized by a Th2-dominated immune response are characterized by either a suppressed cellular immune response or excessive humoral response.

As used herein, a disease characterized by a an excess of Th2
5 cytokine activity refers to a state, disease or condition where the algebraic sum of cytokines in a specific microenvironment in the body or in a lesion(s) or systemically is predominantly of the Th2 type, dominated by IL-4 and/or IL-10 and/or TGF- β . Diseases, states or conditions that exhibit enhanced Th2 responses include infectious diseases such as, but
10 are not limited to, chronic hepatitis C virus infection, leprosy toxoplasmosis infection and AIDS. Imbalance in favor of Th2 cells also occurs in asthma and lupus and other diseases that exhibit suppressed cellular immunity.

Thus, the cells produced by the methods herein, which are
15 predominantly Th1 cells, are used to treat diseases characterized by an excess of Th2 cytokine activity or lack of Th1 cytokine activity. Hence methods for treatments of such diseases are provided. The methods and cells enhance the cellular immune response or effect a switch from a Th2-dominated immune response to a Th1-dominated immune response in
20 subjects.

As used herein, treatment means any manner in which the symptoms of a condition, disorder or disease are ameliorated or otherwise beneficially altered. Treatment also encompasses any pharmaceutical use of the compositions herein.

25 As used herein, a vaccine is a composition that provides protection against a viral infection, cancer or other disorder or treatment for a viral infection, cancer or other disorder. Protection against a viral infection, cancer or other disorder will either completely prevent infection or the tumor or other disorder or will reduce the severity or duration of infection,

-19-

tumor or other disorder if subsequently infected or afflicted with the disorder. Treatment will cause an amelioration in one or more symptoms or a decrease in severity or duration. For purposes herein, a vaccine results from co-infusion (either sequentially or simultaneously) of an
5 antigen and a composition of cells produced by the methods herein. As used herein, amelioration of the symptoms of a particular disorder by administration of a particular composition refers to any lessening, whether permanent or temporary, lasting or transient that can be attributed to or associated with administration of the composition.

10 As used herein, substantially pure means sufficiently homogeneous to appear free of readily detectable impurities as determined by standard methods of analysis, such as flow cytometry, used by those of skill in the art to assess such purity, or sufficiently pure such that further purification would not detectably alter the physical and chemical properties, such as
15 biological activities, of the substance. Methods for purification of the immune cells to produce substantially pure populations are known to those of skill in the art. A substantially pure cell population, may, however, be a mixture of subtypes; purity refers to the activity profile of the population. In such instances, further purification might increase the
20 specific activity of the cell population.

As used herein, biological activity refers to the *in vivo* activities of immune cells or physiological responses that result upon *in vivo* administration of a cell, composition or other mixture. Biological activity, thus, encompasses therapeutic effects and pharmaceutical activity of
25 such cells, compositions and mixtures.

Although any similar or equivalent methods and materials can be employed in the practice of the methods and cells provided herein, exemplary embodiments are described.

-20-

B. Problems with prior methods and solutions provided herein

The methods provided herein overcome the problems that have hindered prior adoptive immunotherapy protocols. The infrequent and sporadic efficacy of prior adoptive cell immunotherapy protocols is a major reason for the failure of these therapies. One reason for the infrequent and sporadic efficacy is associated with the variations in the source material collected from subjects. Subjects present with a wide variety of hematological profiles. These variations are especially apparent in cancer subjects that have been previously treated with cytotoxic chemotherapy drugs. Due to the fact that the source material collected from each individual subject is different, it is not unexpected that the prior adoptive immunotherapy protocols that utilized unpurified source material resulted in a final cell population that varied subject to subject. These variations can explain the sporadic efficacy observed in these prior methods.

Another reason for the infrequent and sporadic efficacy of prior adoptive cell immunotherapy is due to the inherent immunosuppression of subjects with cancer and some infectious diseases. In many cases the mechanisms that originally suppressed the host immune response from eradicating the tumor or the pathogen are too powerful and well established for prior adoptive immunotherapy methods to overcome. The cells that result from these methods are capable of producing significant quantities of immunostimulatory cytokines even in the presence of immunosuppressive cytokines. Further, the Th1 cytokines produced by the cells resulting from the methods provided herein, due to their cross regulatory action, can down regulate Th2-mediated suppressive action in these subjects.

Th1 cells for Adoptive Immunotherapy

Th1 cells promote the cytotoxic and inflammatory reactions, such as delayed type hypersensitivity (DTH) mediated through effector cells such as NK cells, cytotoxic T lymphocytes (CTL) and macrophages. Th2
5 cells suppress the cellular immune response and promote antibody (Ab) production, isotype switching and eosinophilic inflammation (Mosmann *et al.* (1989) *Annual Review of Immunology* 7:145; Yamamura (1992) *Science* 255:12; Yamamura *et al.* (1991) *Science* 254:277 (published erratum appears in *Science* 1992 Jan 3;255(5040):12; and Cher *et al.*
10 (1987) *Journal of Immunology* 138:3688). Cancer subjects and tumor-bearing animals have been shown to exhibit suppressed cellular immune responses as evidenced by decreased DTH, CTL function and NK activity (Broder (1978) *Journal of Medicine* 299:1335), not because of lack of effector cells but rather due to a lack of Th1 regulatory cells. The
15 effector cells are present in these subjects in sufficient quantities, but do not function because of a lack of Th1 regulatory cell help. Prior adoptive immunotherapy sought to enhance the number of effector cells (NK, cytotoxic T-cells and macrophages). Without Th1 regulatory cell support the infused effector cells are as impotent as the resident effector cells,
20 explaining the poor efficacy of prior methods.

Enhanced Th2 responses, creating an immunosuppressive state, are present in infectious diseases such as chronic hepatitis C virus infection (Fan *et al.* (1998) *Mediators of Inflammation* 7:295), leprosy (Yamamura (1992) *Science* 255:12), toxoplasmosis infection (Sher *et al.* (1992)
25 *Immunological Reviews* 127:183) and AIDS (Clerici *et al.* (1993) *Immunology Today* 14:107). Imbalance in favor of Th2 cells also occurs in asthma (Robinson *et al.* (1992) *New England Journal of Medicine* 326:298) and lupus (Funauchi *et al.* (1998) *Scandinavian Journal of Rheumatology* 27:219).

-22-

Excess production of Th2 cytokines and/or depressed production of Th1 cytokines resulting in a Th1/Th2 cytokine imbalance has also been reported in virtually all types of cancer tested, including renal cell carcinoma (RCC) (Onishi *et al.* (1999) *Bju International* 83:488; Elsässer-Beile *et al.* (1998) *Tumour Biology* 19:470; Nakagomi *et al.* (1995) *International Journal of Cancer* 63:366; Schoof *et al.* (1993) *Cellular Immunology* 150:114; Wang *et al.* (1995) *International Journal of Cancer* 61:780), melanoma (Chen *et al.* (1994) *International Journal of Cancer* 56:755; Krüger-Krasagakes *et al.* (1994) *Journal of Cancer* 70:1182; Fortis *et al.* (1996) *Cancer Letters* 104:1), prostate cancer (Hrouda *et al.* (1998) *British Journal of Urology* 82:568), digestive cancer (Tabata *et al.* (1999) *American Journal of Surgery* 177:203), colon cancer (Berghella *et al.* (1998) *Cancer Immunology, Immunotherapy* 45:241), colorectal cancer (Pellegrini *et al.* (1996) *Cancer Immunology, Immunotherapy* 42:1), pancreatic and gastric adenocarcinoma (Fortis *et al.* (1996) *Cancer Letters* 104:1; Bellone *et al.* (1999) *American Journal of Pathology* 155:537), head and neck cancer (Prasad *et al.* (1998) *Journal of the American College of Nutrition* 17:409), non-small cell lung cancer (Asselin-Paturel *et al.* (1998) *Journal of Cancer* 77:7; Huang *et al.* (1996) *Journal of Immunology* 157:5512), lung cancer (Chen *et al.* (1997) *Chest* 112:960; Ito *et al.* (1999) *Cancer* 85:2359), bronchogenic carcinoma (Smith *et al.* (1994) *American Journal of Pathology* 145:18), gynecological tumors (Punnonen *et al.* (1998) *Cancer* 83:788; al-Saleh *et al.* (1998) *Journal of Pathology* 184:283; Jacobs *et al.* (1998) *Clinical and Experimental Immunology* 111:219), breast cancer (Rosen *et al.* (1998) *Cancer Letters* 127:129; Goedegebuure *et al.* (1997) *Cellular Immunology* 175:150), ovarian cancer (Goedegebuure *et al.* (1997) *Cellular Immunology* 175:150), B cell chronic lymphocytic leukemia (de Toter *et al.* (1999) *British Journal of Haematology* 104:589), cutaneous

- T-cell lymphoma (Hirshberg *et al.* (1999) *American Journal of Hematology* 60:143; Di Renzo *et al.* (1997) *Immunology* 92:99), gastric lymphoma (Hauer *et al.* (1997) *Journal of Clinical Pathology* 50:957), T-cell leukemia and the Sezary syndrome (Saed *et al.* (1994) *Journal of Investigative*
- 5 *Dermatology* 103:29; Tendler *et al.* (1994) *Cancer Research* 54:4430), Hodgkin's disease (Serrano *et al.* (1997) *Haematologica* 82:542; Clerici *et al.* (1994) *European Journal of Cancer* 30A:1464; Damle *et al.* (1991) *Cancer Immunology, Immunotherapy* 34:205), thymoma (Fujisao (1998) *British Journal of Haematology* 103:308), glioma (Huettnner *et al.* (1995)
- 10 *American Journal of Pathology* 146:317; Roussel *et al.* (1996) *Clinical and Experimental Immunology* 105:344) glioblastoma (Ashkenazi *et al.* (1997) *Neuroimmunomodulation* 4:49), basal and squamous cell carcinoma (Kim *et al.* (1995) *Journal of Immunology* 155:2240; Yamamura *et al.* (1993) *Journal of Clinical Investigation* 91:1005).
- 15 A Th1 immune response to a tumor is protective, while a Th2 response permits tumors to implant and progress. For example, in murine models of B cell leukemia/lymphoma and melanoma the animals susceptible to tumor challenge developed a Th2 immune response, while animals that developed a Th1 immune response were protected (Lee *et al.*
- 20 (1997) *Blood* 90:1611). IL-4 released by tumor-associated Th2 cells in mice receiving B16 melanoma cells strongly enhances the extent of pulmonary metastases (Kobayashi *et al.* (1998) *Journal of Immunology* 160:5869). Conversely, Th1 cytokine expression has been associated with spontaneously regressing melanoma in humans (Lowes *et al.* (1997)
- 25 *Journal of Investigative Dermatology* 108:914). Similarly, Th2 cytokine dominance is associated with hematopoietic suppression, while Th1 dominance is associated with hematopoietic improvement after thymectomy in subjects with thymoma (Fujisao (1998) *British Journal of Haematology* 103:308). Subjects with digestive cancers have been

-24-

shown to have a significant increase in the proportion of Th2-producing cells compared to healthy controls. The proportion of these cells were significantly reduced one month after surgical excision of the tumor (Tabata *et al.* (1999) *American Journal of Surgery* 177:203). Similarly, a

5 Th1-dominated immune response was found in tumor tissue of operable subjects with lung cancer and a Th1 to Th2 shift occurred with tumor progression (Ito *et al.* (1999) *Cancer* 85:2359). In murine renal cell carcinoma (RCC) and colon adenocarcinoma a gradual loss of Th1 cells and an increase in Th2 cytokines was shown to occur as tumor growth

10 progressed (Ghosh *et al.* (1995) *Journal of the National Cancer Institute* 87:1478). Mice bearing primary MC tumors had significantly diminished T-cell and NK-cell functions and impaired capacity to produce Th1 cytokines (Horiguchi *et al.* (1999) *Cancer Research* 59:2950). In subjects with RCC, an increase in Th2 cytokines was observed that correlated with

15 the stage and grade of the malignancy (Onishi *et al.* (1999) *Bju International* 83:488). Similar findings have been reported in subjects with other types of advanced cancers (Sato *et al.* (1998) *Anticancer Research* 18:3951).

Immunosuppression in Cancer Subjects

20 The immunosuppressive environment in a cancer subject is created in large part by the tumor cells. Tumors appear to produce or create a Th2-biased environment (immunosuppressive environment), which protects the tumor against an immune attack. Tumor cells create a cytokine milieu capable of suppressing an anti-tumor immune response by

25 down-regulating the function of Th1 cells.

Tumor cells are known to produce a variety of Th2 cytokines (Chen *et al.* (1994) *International Journal of Cancer* 56:755; Asselin-Paturel *et al.* (1998) *Journal of Cancer* 77:7; Smith *et al.* (1994) *American Journal of Pathology* 145:18; Vowels *et al.* (1994) *Journal of Investigative*

Dermatology 103:669; Nitta *et al.* (1994) *Brain Research* 649:122). Tumor infiltrating cells also produce Th2 cytokines (Roussel *et al.* (1996) *Clinical and Experimental Immunology* 105:344). Freshly isolated RCC cells produce IL-10 (Nakagomi *et al.* (1995) *International Journal of Cancer* 63:366; Wang *et al.* (1995) *International Journal of Cancer* 61:780), a Th2 cytokine. IL-10 is a potent inhibitor of tumor cytotoxicity (Nabioullin *et al.* (1994) *Journal of Leukocyte Biology* 55:437) and reduces the proliferation and IFN- γ production (a Th1 cytokine) of peripheral blood T-cells and T-cell clones (Taga *et al.* (1993) *Journal of Immunology* 150:4754; de Waal Malefyt *et al.* (1993) *Journal of Immunology* 150:4754). RCC supernatants increase the production of IL-10 from macrophages (Ménétrier-Caux *et al.* (1999) *British Journal of Cancer* 79:119). The Th2 cytokines, IL-10 and IL-4, are also produced by RCC TIL (Schoof *et al.* (1993) *Cellular Immunology* 150:114; Wang *et al.* (1995) *International Journal of Cancer* 61:780; Maeurer *et al.* (1995) *Cancer Immunology, Immunotherapy* 41:111). IL-10 serum levels are increased in sera of subjects with solid tumors and correlates with poor responsiveness and decreased survival (De Vita *et al.* (2000) *Oncology Reports* 7:357). Increased serum concentrations of IL-10 can be a predictor of unfavorable outcome in RCC (Elsässer-Beile *et al.* (1999) *Cancer Immunology, Immunotherapy* 48:204). RCC cells also produce other immunosuppressive cytokines, such as IL-6, IL-8 and TGF- β .

IL-8 suppresses the toxicity and can significantly ablate the anti-tumor effect of IL-2 (Heniford *et al.* (1994) *Journal of Surgical Research* 56:82). TGF- β inhibits IFN- γ -induced class II MHC expression (Banu *et al.* (1999) *Kidney International* 56:985), preferentially induces APC to secrete IL-10, and concomitantly suppresses the production of the Th1-inducing cytokine, IL-12 (D'Orazio *et al.* (1998) *Journal of Immunology* 160:2089) and suppresses antigen-specific activation and cytokine

-26-

secretion by memory Th1 cells (Lúdvíksson *et al.* (2000) *European Journal of Immunology* 30:2101). The cytokines produced by RCC have also been shown to modulate T lymphocyte blast formation (Knoefel *et al.* (1997) *Journal of Interferon and Cytokine Research* 17:95). These data
5 show that tumor cells create a cytokine milieu capable of suppressing an anti-tumor immune response by down-regulating the function of Th1 cells.

Although human tumors are often infiltrated by a variety of inflammatory cells, these cells are ineffective. Subjects with RCC often have infiltrating lymphocytes capable of recognizing and responding to
10 autologous tumor (Finke *et al.* (1994) *Journal of Immunotherapy with Emphasis on Tumor Immunology* 15:91; Finke *et al.* (1992) *Journal of Immunotherapy* 11:1). Tumor growth occurs despite the presence of these cells. The local production of Th2 cytokines by the tumor cells explains the ineffectiveness of these infiltrating cells.

15 These observations explain why attempts at adoptive immunotherapy using immune effector cells such as LAK, TIL and CTL have resulted in limited efficacy. The failure of an effective antitumor immune response appears to be due primarily to a deficiency of Th1 cells, rather than an absence of effector cells capable of recognizing tumors.
20 Effector cells would not be expected to function in hosts with Th2-dominated immunity. These effector cells require a Th1-dominated environment to function.

Accordingly, it is not desirable to infuse effector cells into subjects with Th2-dominated immunity. Effector cells cannot function in the
25 immunosuppressive environment of hosts with cancer and infectious diseases.

-27-

Restoring Th1/Th2 Balance is Therapeutic

In order to overcome the immunosuppression in hosts with cancer and infectious diseases, it is desirable to correct the Th1/Th2 imbalance. Adoptive transfer studies in mice have confirmed that changing the
5 regulatory cell balance in immunopathological disease states by adoptive transfer of regulatory Th1 or Th2 cells can be therapeutic. As described previously (see, U.S. application Serial No. 08/506,668, converted to U.S. provisional application Serial No. 60/044,693, now abandoned; co-
10 pending U.S. applications Serial Nos. 08/700,565, 09/127,411, 09/127,142, 09/127,138, 09/127,141, 09/824,906, and published International PCT application No. WO 97/05239), regulating the Th1/Th2 cell balance is therapeutic.

For example, adoptively transferred Th2 cells suppress Th1-mediated disease in animal models of uveoretinitis (Saoudi *et al.* (1993)
15 *European Journal of Immunology* 23:3096), IDDM (Han *et al.* (1996) *Journal of Autoimmunity* 9:331), multiple sclerosis (Nicholson *et al.* (1995) *Immunity* 3:397) and allotransplantation (Fowler *et al.* (1994) *Blood* 84:3540; Fowler *et al.* (1994) *Progress in Clinical and Biological Research* 389:533). Adoptive transfer of Th1 clones protects animals
20 against infection with the protozoan *Leishmania major* (Powrie *et al.* (1993) *European Journal of Immunology* 23:3043), genital infection with *chlamydia trachomatis* and murine *candidiasis* (Romani *et al.* (1991) *Infection and Immunity* 59:4647; Igietseme *et al.* (1999) *Cancer Immunology, Immunotherapy* 48:204; Ramsey *et al.* (1993) *Regional*
25 *Immunology* 5:317).

Regulating Th1/Th2 balance in cancer is also therapeutic. The critical role for Th1-dominant immunity in tumor immunology is known (see, *e.g.*, Nishimura *et al.* (2000) *Cancer Chemotherapy and Pharmacology* 46 Suppl:S52, for a review). For example, an extract from

-28-

Mycobacterium tuberculosis, designated Z-100, restores Th1/Th2 balance in tumor-bearing mice (Oka *et al.* (1999) *Immunology Letters* 70:109) and inhibits pulmonary metastasis of B16 melanoma (Kobayashi *et al.* (1997) *Anti-Cancer Drugs* 8:15691) and Lewis lung carcinoma (Emori *et al.* (1996) *Biotherapy* 9:249). Z-100 is also a useful adjuvant in the treatment of oral cancer (Okutomi *et al.* (2000) *Gan To Kagaku Ryoho (Japanese Journal of Cancer and Chemotherapy)* 27:65). Alkylating agents such as cyclophosphamide can cause complete remissions in tumor-bearing mice by changing the immune status from Th2-dominance to Th1-dominance (Inagawa *et al.* (1998) *Anticancer Research* 18:3957; Li *et al.* (1998) *Journal of Surgical Oncology* 67:221). Treatment of mice bearing large MOPC-315 tumors with L-phenylalanine mustard therapy stimulates anti-tumor immunity by causing a shift in cytokine production from Th2 to Th1 (Gorelik *et al.* (1994) *Immunology, Immunotherapy* 39:117). The streptococcal preparation, OK-432, induce a Th1-dominate state in mice (Fujimoto *et al.* (1997) *Journal of Immunology* 158:5619; Okamoto *et al.* (1997) *International Journal of Cancer* 70:598) and has a potent anti-tumor effect in humans (Kitahara *et al.* (1996) *Journal of Laryngology and Otology* 110:449). The immunomodulator, AS101, has anti-tumor properties mediated through the stimulation of Th1 cytokine release in subjects and tumor-bearing mice (Sredni *et al.* (1996) *Journal of the National Cancer Institute* 88:1276; Sredni *et al.* (1996) *International Journal of Cancer* 65:97; Sredni *et al.* (1995) *Journal of Clinical Oncology* 13:2342). Intravesical Bacillus Calmette-Guerin (BCG) immunotherapy is an optimal choice for treatment of aggressive superficial bladder cancer, with a 70% response rate. The mechanism of BCG's therapeutic effect is through the stimulation of an increase in the production of Th1 cytokines (Thanhäuser *et al.* (1995) *Cancer Immunology, Immunotherapy* 40:103). Mistletoe extracts have antitumor activity in mice (Weber *et al.* (1998)

Arzneimittel-Forschung 48:497; Yoon *et al.* (1998) *International Journal of Immunopharmacology* 20:163) and have positive affects on the quality of life in advanced cancer subjects (Friess *et al.* (1996) *Anticancer Research* 16:915). These effects appear to be mediated by stimulation of

5 Th1 cytokines.

TCR-based vaccines that induce a Th1 immune response provide tumor protection in mice (Wong *et al.* (1999) *Journal of Immunology* 162:2251). Induction of antitumor CTL in mice bearing p53+ tumors is associated with measurable defects in the function of dendritic cells (DC).

10 Tumor progression is associated with change of the balance Th1/Th2 cells in favor of the Th2-like cytokine profile, while effective immunization is associated with a shift to the Th1 phenotype (Gabrilovich *et al.* (1996) *Cellular Immunology* 170:111). DC-induced antitumor effects are completely blocked by co-administration of neutralizing monoclonal antibody

15 directed against Th1-associated cytokines (such as IL-12, tumor necrosis factor alpha and IFN- γ) (Zitvogel *et al.* (1996) *Journal of Experimental Medicine* 183:87). Down-regulation of the Th2 response in tumor-bearing mice by treatment with anti-IL-4 mAb significantly suppresses growth of RENCA (murine renal cell carcinoma) tumors (Takeuchi *et al.* (1997)

20 *Cancer Immunology, Immunotherapy* 43:375), while IL-2 gene transfected RENCA cells mediate tumor rejection (Hara *et al.* (1996) *Japanese Journal of Cancer Research* 87:724).

Adoptive immunotherapy experiments have also demonstrated the therapeutic utility of inducing Th1-dominated immunity to treat viral

25 diseases. For example, transfer of influenza-specific Th1 cells was protective against influenza infection, while Th2 infusion failed to induce protection (Graham *et al.* (1994) *Journal of Experimental Medicine* 180:1273).

-30-

Polyclonal Th1 cells for Adoptive Immunotherapy

Animal models of cancer have demonstrated that optimally prepared, adoptively transferred CD4+ T cells can reject established tumors with great efficiency even when targeted tumor cells express no MHC Class II molecules, implying that recognition of tumor antigen (Ag) occurs via MHC Class II-expressing host antigen-presenting cells (APC) within the tumor. Because consequent rejection also excludes Ag-specific contact between CD4+ T cells and MHC Class II negative tumor cells, the most critical CD4+ T-cell-mediated event is likely Th1 cytokine release, resulting in an accumulation and activation of accessory cells such as tumoricidal macrophages and lymphokine-activated killer cells (Cohen *et al.* (2000) *Critical Reviews in Immunology* 20:17).

Polyclonal Th1 cells, by virtue of their cytokine release, provide a general immune system boost that could deviate an on-going immune response from Th2 to Th1. This is supported by the observation that polyclonal Th1 cells administered to mice with non-immunogenic tumors results in rejection of 60-90% of the tumors. Animals cured by this treatment developed a tumor-specific memory and were capable of rejecting re-challenges with the same tumor (Saxton *et al.* (1997) *Blood* 89:2529). Similarly, co-injection of a PPD-specific Th1 clone, not capable of being activated by the tumor, and PPD antigen in a murine metastatic tumor model resulted in anti-metastatic effects and anti-tumor activity (Shinomiya *et al.* (1995) *Immunobiology* 193:439). Activated and expanded L-selectin- CD4+ T cells demonstrating a Th1 cytokine profile have also been shown to have excellent antitumor efficacy in mice (To *et al.* (2000) *Laryngoscope* 110:1648).

Accordingly, polyclonal Th1 cells that are activated *ex vivo* are desired for adoptive immunotherapy of human disease. Infusion of activated polyclonal Th1 cells could act by either suppressing the

-31-

production of Th2 cytokines from all sources in subjects or by causing a shift in the immune response from Th2 to Th1. These cells by virtue of their ex vivo activation would not be under the influence of disease-specific immunosuppressive cytokines. Infused polyclonal Th1 cells also

5 mediate enhanced cellular immune function through cell-to-cell contact, such as via the expression of CD40L which acts to cause macrophages to produce IL-12, a known immuno-enhancing cytokine. Polyclonal Th1 cells, via the production of IL-2, also act by stimulating semi-activated effector cells (NK, CTL) in tumor lesions. A combination of these known

10 and other unknown mechanisms will result in enhanced cellular immunity after activated polyclonal Th1 cell infusion. The natural immune system under the influence of Th1 cytokines shifts the immune response to Th1 through the recognition of unknown disease associated antigens.

It is also desirable to have a process which can reproducibly

15 produce highly pure populations of activated polyclonal Th1 cells for infusion. It is important that the expanded cells be highly pure to prevent the infusion of more Th2 cells than were removed from the subject. The infusion of Th2 cells could make the disease worse and can also, due to their cross-regulatory effect, inactivate the beneficial Th1 cells.

20 It is also desirable that the cells for infusion be processed in serum-free medium to avoid the expense and regulatory concerns associated with production of biological products for human infusion in serum containing medium. Autologous serum supplementation is also not desired due to the immunosuppressive factors resident in the serum of

25 subjects with cancer and other Th2 dominated diseases.

-32-

Cell Trafficking

Activated polyclonal Th1 cells are efficacious due to the bystander effect of the proinflammatory cytokines they produce. In order for polyclonal Th1 cells to have a therapeutic effect, it is advantageous for
5 them to produce their proinflammatory cytokines in the vicinity of the tumor or other disease lesions. This requires that the cells traffic to the sites of inflammation or to tumors following their infusion.

In adoptive cell therapy protocols it is desirable to develop a population of cells that have the ability to traffic to tumors or sites of
10 inflammation where they can influence the local environment. *Ex vivo* cell processing of cells for adoptive transfer does not always lead to the production of cells that traffic to tumor lesions. Previous studies with gene marked TIL cells and peripheral blood lymphocytes (PBL) show that these adoptively transferred cells are detected circulating in the peripheral
15 blood for up to 99 days after infusion. No convincing pattern of preferential trafficking of TIL versus PBL to tumor was noted (Economou *et al.* (1996) *Journal of Clinical Investigation* 97:515). The methods provided herein result in Th1 memory cells that traffic to tumors and sites of inflammation.

20 It is known that T-cells that express an activated memory phenotype will selectively accumulate within tumor lesions and other sites of inflammation. Activated memory T-cells have a CD3+, CD25+, CD45RO+, CD62L^{lo} phenotype. It is also known that the expression of CD44 can enhance the ability of cells to infiltrate tissues. The methods
25 provided herein produce highly pure populations of Th1 cells that have an activated memory phenotype. The methods herein involve purification of Th1 cells precursors, such as CD4+, CD45RA+ T-cells, and their subsequent differentiation and expansion. The methods are also

-33-

designed to minimize or substantially or completely eliminate any Th2 cell contamination in the final product.

High Toxicity of Prior Adoptive Immunotherapy Procedures

The toxicity of adoptive immunotherapy treatments has been
5 associated with the use of the growth factor, IL-2. Exogenous IL-2, also known as "T-cell Growth Factor", is used in adoptive immunotherapy for the differentiation of immune cells into cytotoxic effector cells and for the ex-vivo expansion of T-cells. The exposure of immune cells to exogenous IL-2 makes them dependent upon the continued presence of IL-2 to
10 maintain their viability and function. This has necessitated the co-infusion of IL-2 with the cells in prior adoptive immunotherapy protocols. The systemic administration of IL-2 results in severe and often life-threatening toxicity.

While toxic, it is known that even non-therapeutic doses of IL-2
15 can significantly enhance the therapeutic efficacy of infused immune cells by inducing in-vivo proliferation and prolonged survival. Therefore, IL-2 is infused routinely in adoptive immunotherapy methods. The reason IL-2, even in non-therapeutic doses, enhances the efficacy of infused cells is because prior adoptive immunotherapy methods produce cells that are not
20 optimally activated. Non-therapeutic doses of IL-2 tend to increase the activation state of the cells providing therapeutic benefit. Infusion of IL-2 and cells together complicates the ability to obtain regulatory approval of the cell infusion as a biological drug, as it is difficult to determine the contribution of the cells separate from the contribution of IL-2.
25 Accordingly, it is desirable to eliminate the need for IL-2 in the differentiation and expansion phases of adoptive immunotherapy, as well as in the infusion phase. Cells resulting from the methods are in a highly activated state (CD25 +) and produce significant amounts of cytokine without further stimulation.

-34-

C. Methods for producing highly pure, activated Th1 cells

Methods for consistently producing a population of highly pure, activated, polyclonal memory Th1 cells from a subject blood sample in the absence of any exogenous growth or differentiation factors (such as IL-2 or IFN- γ) for use in adoptive immunotherapy are provided. The methods provided herein include the steps of: (i) the collection of source material from a subject; (ii) the purification of T-cells from the source material; (iii) the frequent (every 2-3 days) activation of the purified T-cells and typically repeated (a minimum of 3 times); and optionally (iv) the reinfusion of the resulting cells into the same subject.

1. Source Cell Collection

In practicing a method provided herein, a starting population of mononuclear cells is collected from a subject by leukapheresis, in order to obtain the greatest starting cell population number. This is the source material. A population of CD3+ T-cells, generally CD4+ cells, is then purified from the source population of mononuclear cells. Purities should be in excess of 90%. These are the starting population of cells. The CD4+ cells can be purified by positive selection as more fully explained below. In subjects with large numbers of Th2 cells resident in the memory cell population (CD45RO+), the CD4+ cells can be further purified in order to obtain a starting population of only naïve CD4+ cells. This is accomplished by purging the CD4+ cells of CD45RO+ cells. Purified CD4+ cells will express CD45RA+ and CD62L^{hi} surface antigens and produce IL-2 upon activation. CD4+ cell populations purified and activated as provided herein contain few, if any, IL-4 producers and also fail to initially make substantial amounts of IFN- γ . The methods provided herein are capable of producing a pure population of activated Th1 memory cells from a starting population of CD4+ cells, as well as capable of enhancing the population of activated Th1 memory

-35-

cells from starting populations of CD3+ cells and CD4+, CD45RO+ cells. It is known that CD4+ cells can develop into cells that principally produce IL-4 or IFN- γ upon restimulation. Prior methods use exogenous cytokines to cause this differentiation *ex vivo*.

5 2. Initial Activation

The starting cells must undergo an activation step in order to develop into Th1 memory cells. Generally it is known that CD4+ cells can be activated by antigen presented on MHC Class II molecules or polyclonal stimulants such as Con A, PMA or anti-CD3. For purposes of
10 herein, an exemplary method of activation method is immobilized anti-CD3/anti-CD28 mAb costimulation. In order to assure the differentiation of Th1 cells after activation, the concentration of IL-4 at the time of activation has to be extremely low or even non-existent. IL-4 is known to have a profound effect on the ability of the CD4+ cells to differentiate
15 into Th2 cells. For example, activation of CD4+ cells in the presence of IL-4 concentrations of as little as 50 pg/ml is enough to cause the population of Th2 cells in the culture to increase greater than 100-fold. This increase is known to be due to differentiation of CD4+ cells into Th2 cells and not the expansion of pre-existing Th2 cells. Therefore, it is
20 important to assure that the starting population of cells collected for the purpose of ex-vivo differentiation of Th1 cells are purged of all cells that are producing IL-4. Failure to purge IL-4 producing cells prior to the initial activation will result in Th2 cell contamination of the final product.

3. Initial Purification

25 Because the starting population of cells must be activated in the absence of IL-4 in order to prevent Th2 differentiation, the cellular sources of IL-4 must be first purged from the starting culture. The cellular source of the early burst of IL-4 that drives Th2 differentiation *in vivo* has not been conclusively identified. Therefore, the exact cell types

-36-

necessary to purge from the starting culture is not clear. Among the cell types that for which purging is recommended are CD117+ granulocytes, basophils, NK cells, and NK1.1 T-cells, which are sources of IL-4 (see, Wang *et al.* (1999) *Clinical Immunology* 90:47; Poorafshar *et al.* (2000) *European Journal of Immunology* 30:2660; Singh *et al.* (1999) *Journal of Immunology* 163:2373; Leite-De-Moraes *et al.* (1998) *European Journal of Immunology* 28:1507; Poynter *et al.* (1997) *Cellular Immunology* 179:22). So at least these subsets of cell are purged from the starting culture.

- 10 Immune cell subsets are commonly purged by using monoclonal antibodies specific for unique cell surface molecules on the target cells. To isolate cells, they can be indirectly stained with specific biotinylated antibody and passed through a avidin-coated column (Handgretinger *et al.* (1994) *Journal of Clinical Laboratory Analysis* 8:443) or the antibodies
- 15 can be immobilized on immunomagnetic beads or particles directly, mixed with the cells and placed under a magnetic field (Mantovani *et al.* (1989) *Bollettino - Societa Italiana Biologia Sperimentale* 65:967; Jacobs *et al.* (1993) *Research in Immunology* 144:141; Partington *et al.* (1999) *Journal of Immunological Methods* 223:195). Alternatively, the cells can be
- 20 labeled with the monoclonal antibody and mixed with immunomagnetic particles coated with species-specific antibodies that bind to the monoclonal antibody specific for the cell surface marker (indirect method) (Hansel *et al.* (1989) *Journal of Immunological Methods* 122:97). Immobilizing the monoclonal antibody to a solid surface, such as a culture
- 25 flask (panning) also can be used (Prince *et al.* (1993) *Journal of Immunological Methods* 165:139), as well as florescent-activated cell sorting techniques.

Negative selection can be performed with a cocktail of monoclonal antibodies (mAb) specific for cell surface markers that are exclusively

-37-

expressed on the unwanted cells. For example, for purging the cells herein, a cocktail containing mAbs to CD19 (B-cells), CD56 (NK cells), CD14 (monocytes/macrophages) and CD8 (cytotoxic T-cells) was used to obtain a population of pure CD4 cells by negative selection. This cocktail
5 when used with immunomagnetic beads results in a pure population of CD4+ cells (>95%) when the cells are derived from normal donors.

For purposes herein, however, negative selection purification techniques are not desirable for purification of the source cells. Negative selection leads to an unknown starting population of cells that can
10 negatively affect the purity of the final product. Subjects with immunologically-mediated diseases, and cancer subjects in particular, present with a wide variety of hematological profiles. Subject blood can have many immature cells with altered surface expression so it is difficult to define a monoclonal antibody cocktail that can purge all unwanted cells
15 from a mononuclear cell sample from every subject. These unidentified cells can contaminate the starting cell population. The same mAb cocktail that results in a pure population of CD4 cells from normal donors, when used on blood samples from cancer subjects, results in CD4 cells with very poor purity (only 30-60% CD4+). The poor purity of the
20 starting population of cells prevents the generation of a high purity final product of Th1 cells.

Therefore, in embodiments herein a positive selection protocol is used in order to isolate pure populations of CD4 cells from subject blood. Positive selection allows the retention of only the desired CD4+ cells,
25 while all the unwanted contaminating cells, of known and unknown phenotypes, are purged from the culture. A method for positive selection is to use an anti-CD4 mAb conjugated to immunomagnetic beads or magnetic particles in order to positively select CD4+ cells from the source subject blood samples.

-38-

Purification of source cells is rarely used in prior adoptive immunotherapy methods and when it is used, negative selection protocols have been preferred. Positive selection is not often used to purify immune cell subsets due to the difficulty of removing the selected cells from the beads after the selection. Physically removing the cells from the beads by gentle agitation results in very pure CD4 cells (greater than 95% CD4+), it also results in a lower yield than negative selection techniques (yields of 50-60% compared to greater than 70% using positive selection). Another problem with positive selection is that significant numbers of cells retain mAb on their CD4 receptors or internalize their CD4 receptors after selection, making it difficult to access the purity of the cells by FACS. This can be solved by waiting 24-48 h before analysis or by staining for CD3+, CD8- cells as an indirect determination of CD4+ cells.

Another reason why positive selection has not been used to purify T-cells, especially CD4+ T-cells, from source material is that such techniques have technical problems when being applied to source material derived from cancer subjects. The positive selection of CD4+ cells directly from mononuclear cells isolated from cancer subjects often lead to a massive loss of viability of the selected CD4 cells. This does not occur when the same positive selection techniques are applied to source material from normal donors. Some macrophages are known to express the CD4 surface marker, it appears that the purification process activates these macrophages causing them to produce a substance that is lethal to CD4+ T-cells. Since cancer subjects have been exposed to many different chemotherapy drugs and radiation treatments, this could predispose the macrophages to produce a lethal substance upon ligation of the CD4 molecule. Accordingly, when practicing the methods herein with cancer subjects, the macrophage component of the source cell

-39-

population should be minimized prior to the CD4 positive selection step.

An exemplary method to reduce the macrophage population is to first incubate the collected mononuclear cells overnight on plastic. This takes advantage of the well known property of macrophages to adhere to a surface. The next morning, the non-adherent fraction of cells can be collected and subjected to positive selection of CD4 cells. Another method is to pass the mononuclear cells through a column of nylon wool prior to CD4 positive selection. Macrophages attach to the nylon wool fibers and are thus removed from the culture. The use of macrophage-specific mAbs and complement also can be used.

Prior removal of the adherent fraction of mononuclear cells enabled CD4 cells to be positively selected from cancer subject mononuclear blood samples without loss of viability.

4. Differentiation of Th1 cells

Activation in the presence of IFN- γ and the absence of IL-4 is generally believed to be required to cause CD4+ to differentiate into Th1 cells. Advantageously, methods provided herein do not require the addition of any cytokines. Also, the methods do not require the presence of macrophages for differentiation, which play a critical role in directing CD4+ cells to differentiate into Th1 or Th2 cells. Macrophages, however, are short-lived in cultures, and thus limit the applicability of methods and compositions that rely macrophages for differentiation. The methods herein, thus, avoid this.

The initial activation of purified CD4+ cells with immobilized anti-CD3 and anti-CD28 induces the cells to produce IL-2 and no IFN- γ . Without further stimulation, the cells expand and differentiate into mixed populations of Th1 and Th2 cells. When the CD4 cells are derived from cancer subject blood, there is sometimes production of detectable amounts of IL-4 in the cultures after the initial activation with anti-

-40-

CD3/anti-CD28. CD4 cells positively selected after depletion of non-adherent monocytes are known to produce IL-4 (Stanciu *et al.* (1996) *J. Immunolog. Methods* 187:107-115).

When IL-4 is detected after the initial activation, a significant
5 amount of the IL-4 was found to be produced by the memory CD4+, CD45RO+ subpopulation of the starting cells. Others have also identified memory cells as a source of IL-4 (Sasama *et al.* (1998) *International Archives of Allergy and Immunology* 117:255).

Because of the Th1/Th2 imbalance in cancer subjects and in other
10 subjects with diseases in which the Th2 phenotype predominates, the memory cell subset of CD4+ cells is enriched in IL-4 producing cells. Therefore, it may be necessary to also purge the CD45RO+ cells from the starting cells to enhance the purity of the final population of Th1 cells. The necessity for this purging step can be determined empirically for a
15 particular subject or disease state, or the step can be routinely included to ensure that such cells, if present, are eliminated.

As described herein, the method provided herein that employs frequent activation with immobilized anti-CD3/anti-CD28 can cause such high amounts of endogenous IFN- γ production from the culture that any
20 contaminating cells with the capacity to produce IL-4 are inhibited. Therefore, while small amounts of IL-4 may be detectable in the early activation steps, IL-4 production becomes negligible after several rounds of activation with anti-CD3/anti-CD28. Therefore, it is rarely required that the CD45RO+ population needs to be purged from the starting cells,
25 even when the source cells are derived from cancer subjects.

If the CD45RO purge step is performed, additional technical issues need to be addressed. After collection of mononuclear cells by leukapheresis, if the CD4 positive selection is performed prior to the CD45RO purge, there is a significant loss of yield. This is because

-41-

residual mAb on CD4 cells causes CD4 cells to be purged with the CD45RO cells. For this reason, in one embodiment the macrophage fraction removed first, and the CD45RO + cells are purged by negative selection followed by positive selection for CD4+ cells. This results in a
5 pure population of viable CD4 + , CD45RA + naïve T-cells (pTh cells).

When processing cancer subject blood, the CD45RO purge step followed by the CD4 positive selection often results in viable cells, even without the macrophage reduction step. This is due to the significant loss of adherent cells during the CD45RO negative selection process. For
10 the most consistent production of Th1 cells from a variety of subject blood, the purge the macrophage population prior to purification of the CD4 or pTh cells should be performed.

Unlike prior methods, the purified pTh or CD4 cells can be caused to differentiate into pure populations of Th1 cells without addition of
15 exogenous cytokines. Activation of pTh cells by a variety of methods, including anti-CD3/anti-CD28, is known to result in the differentiation of Th2 cells. Naive CD4 + cells are a significant source of IL-4 (Noben-Trauth *et al.* (2000) *Journal of Immunology* 165:3620; Demeure *et al.* (1995) *European Journal of Immunology* 25:2722). It has been reported
20 that almost every single naive human CD4 T cell primed and expanded in the absence of exogenous IL-4 releases sufficient autocrine IL-4 to support differentiation into Th2 cells (Yang *et al.* (1995) *European Journal of Immunology* 25:3517).

It was found herein, however, that when pTh cells or CD4 + cells
25 were repeatedly and frequently (about every 2-3 days) activated with anti-CD3/anti-CD28 that they do not produce IL-4. Upon each stimulation, the cells produced increasing amounts of IFN- γ . In particular, it is shown herein, that when pTh cells or CD4 cells are repeatedly (minimum of 3 times) and frequently (every 2-3 days) activated with anti-

-42-

CD3/anti-CD28 that they do not produce IL-4. Upon each stimulation, the cells produce increasing amounts of IFN- γ . The repeated activation causes such large amounts of IFN- γ to be produced that it compensates for a poor quality initial purification and still resulting in highly pure Th1 memory cells at the end of the process. The large amounts of IFN- γ produced into the culture act to inhibit any production of IL-4 by contaminating cells. Activation at a frequency of every 2-3 days for a period of about 9-14 days consistently results in the differentiation of highly pure populations of Th1 memory cells even if the starting population is CD3+ T-cells (CD4+ cells contaminated with CD8+ cells; see, EXAMPLES).

5. Expansion Without IL-2

CD4 cells purified from cancer subjects and activated with immobilized anti-CD3/anti-CD28 do not expand efficiently without the addition of exogenous IL-2. It is known that T-cells from normal donors expand without exogenous IL-2 after being stimulated with anti-CD3/anti-CD28 (see, (Ledbetter *et al.* (1985) *Journal of Immunology* 135:2331; Levine *et al.* (1997) *Transplantation Proceedings* 29:2028). When the cells are derived from cancer subject blood, however, the addition of exogenous IL-2 is required to create optimal growth conditions for anti-CD3/anti-CD28 activated T-cells from cancer subjects (Garlie *et al.* (1999) *Journal of Immunotherapy* 22:336). There are no reports of successful expansion of cancer-derived T-cells without the use of exogenous IL-2.

Source cells from cancer subjects were found to contain significant amounts of TGF-beta. TGF-beta is known to down regulate T-cell proliferation. Significant amounts of the TGF-beta appear to originate from platelets, which are a known source of TGF-beta (Werz *et al.* (1996) *Pharmazie* 51:893). Processing of subject blood causes the release of significant amounts of TGF-beta presumably from the platelets, whereas

-43-

TGF-beta release is not evident in cultures of processed normal blood. It is not known why the platelets from cancer subjects release TGF-beta during processing, but it may be related to the effect of radiation and chemotherapeutic drugs on the fragility of the platelets. Increased plasma
5 levels of TGF-beta have been reported in subjects with cancer (Jiang *et al.* (1995) *Acta Haematologica* 94:1).

Accordingly, the platelet population is reduced in the collected mononuclear cells prior to any processing. This can be achieved, for example, by centrifuging the collected mononuclear cells, such as
10 centrifugation for about 2-5 minutes at 150 x g, followed by purging the platelet rich supernatant. Purging platelets from the starting population of mononuclear cells permits cancer subject T-cells to be efficiently expanded with anti-CD3/anti-CD28 mAb without the requirement for exogenous IL-2 addition.

15 The isolation of pure CD4+ T-cells from subject blood, and the subsequent activation of the cells repeatedly with immobilized anti-CD3 and anti-CD28 mAb results in the expansion of these cells without exogenous cytokines and consistently generates activated Th1 memory cells with high purity. These resulting Th1 memory cells produce large
20 amounts of IFN- γ and no detectable IL-4 and express an activated memory phenotype (CD3+, CD4+, CD45RO+, CD62L-, CD25+, CD44+).

D. Practice of the therapeutic methods

The therapeutic methods herein are designed to produce
25 compositions containing clinically relevant (at least 10^9 , preferably 10^{10} cells or more, generally in a volume of a liter, 500 mls, 200 mls, 100 mls or less) populations of polyclonal memory Th1 cells for infusion for treatment of the diseases or conditions characterized by suppression of the cellular immune response, by over-expression of the humoral immune

-44-

response, excess Th2 activity or a lack or decreased Th1 activity. The methods herein do not rely or use any agents for expansion or differentiation that must be present after expansion to maintain cell viability or activity.

- 5 The compositions contain highly (greater than 70%, 80%, 90% or more of the cells) pure populations of polyclonal memory Th1 cells. Such compositions are used therapeutically for treatment of the diseases, such as cancer, infectious diseases, allergic diseases and other diseases or conditions characterized by suppression of the cellular immune
- 10 response, by over-expression of the humoral immune response, excess Th2 activity or a lack or decreased Th1 activity.

Administration

The compositions of cell can be administered by any suitable means, including, but not limited to, intravenously, parenterally, or locally.

- 15 The particular mode selected will depend upon the particular treatment and trafficking of the cells. Typically, about 10^{10} - 10^{11} cells can be administered in a volume of a 50 ml to 1 liter, 50 ml to 250 ml, 50 ml to 150, and typically 100 ml. The volume will depend upon the disorder treated and the route of administration. The cells can be administered in
- 20 a single dose or in several doses over selected time intervals in order to titrate the dose.

Vaccines

- Also provided herein vaccines that are a combination of the cells produced herein and an immunizing antigen, and methods of vaccinating
- 25 by co-infusing, either sequentially or simultaneously, the cells produced herein and an immunizing antigen, such as tumor-associated antigens, viral antigens, bacterial antigens and other any such antigens. The vaccines can be immunoprotective or can ameliorate symptoms of a disease or treat such disease, for example, by increasing an immune

-45-

response such as the immune response against tumor-associated antigens.

The cells produced by the methods provided herein can be co-infused with an antigen or the antigen and cells can be administered
5 separately, sequentially or intermittently.

The following examples are included for illustrative purposes only and are not intended to limit the scope of the invention.

EXAMPLE 1

10 Materials and Methods

A. Isolation of human lymphocytes.

Samples of buffy coats or leukapheresis products from normal donors and EDTA-preserved blood samples from advanced cancer subjects with a variety of indications and prior treatments were used.

15 Human peripheral blood lymphocytes (PBMC) were isolated using a density gradient centrifugation procedure.

B. Characterization of PBMC samples

Purified PBMC samples were characterized by immuno-phenotyping using flow cytometry. Briefly, cells were incubated with fluorochrome-
20 labeled antibodies in the dark for 30 min., washed of excess antibodies and analyzed on FACSCalibur flow cytometer (BD Biosciences). Results of the analysis were expressed as percentages of total lymphocytes, monocytes, granulocytes, and also subsets of lymphocytes: B-cells, cytotoxic T lymphocytes, CD4 positive T-helpers, and NK cells. The
25 subset of CD4 positive T cells was analyzed for the ratio between naïve CD45RA positive cells and CD45RA negative memory cells.

-46-

C. Cytokine profiling

To determine the ability of freshly purified CD4 positive cells to express IFN- γ and IL-4 an intra-cellular cytokine (ICC) staining procedure using an Internal Cellular Cytokine (ICC) kit (BioErgonomics, St. Paul, MN) was performed. According to the manufacturer's recommendation, PBMC were stimulated for 20 h in T-cell activation medium, stained first by surface anti-CD4 antibodies, fixed, permeated and then stained with intracellular anti-IFN- γ and anti-IL-4 antibodies. Samples were analyzed by flow cytometry and results were presented as percentages of IFN- γ and IL-4 expressing cells in CD4 positive T cells subset.

D. Isolation of T-cell subpopulations

Isolation of specific T-cell subpopulations was performed using two different techniques: sort by flow cytometry on FACSCalibur and sort by combination of positive and negative immunomagnetic selection on AutoMacs (Miltenyi, Germany). To obtain cell samples with high purity, sort by flow cytometry was done. Briefly 4×10^7 of PBMC were stained with anti-CD4 antibodies alone or in combination with anti-CD45RO antibodies, labeled with the corresponding fluorochrome. Subsets of CD4-positive, CD4-positive/CD45RO-negative and CD4-positive/CD45RO-positive cells were collected by sorting and used for expansion experiments. To obtain better yields with 5-10% lower purities, separation for further applications used immunomagnetic selection.

According to the manufacturer's recommendation, up to 2×10^8 cells were incubated with anti-CD4 antibodies conjugated directly to magnetic microbeads and separated on magnetic columns. If needed, the second round of selection was performed using mouse anti-CD45RO antibodies in complex with goat anti-mouse antibodies conjugated to microbeads.

-47-

E. Activation of cells

Sorted cells were plated into cell culture plates at starting concentrations of 1×10^5 to 3×10^5 cells/ml using *ex vivo* serum free cell culture medium (X-VIVO-15 from BioWhittaker) without supplementation.

- 5 The cells were cultured for 12 days and were repeatedly activated using a combination of CD3/CD28 antibodies conjugated to magnetic beads (T-cell Expander, Dynal) every 3 days, starting from the day of sort.

Initial cell activation was performed using 3:1 ratio between magnetic beads and sorted cells. For re-stimulation, an amount of beads
10 equal to the amount of cells in the culture determined by hand cell count was used. On day 13, 14 or 15 expanded cell cultures were harvested. The cells were counted cells (manual hand count) and the final product was characterized.

F. Phenotyping

- 15 For characterization of the final product, the phenotypes of harvested cells were determined, their ability to express IFN- γ and IL-4 by intra-cellular cytokine staining (ICC) and their production of IFN- γ , IL-2 and IL-4 (determined by ELISA in the cell culture supernatants of expanded cells before harvesting) were analyzed. Immunophenotyping
20 and ICC experiments were performed as described above. ELISA assays were performed using ELISA kits (R&D, Minneapolis, MN) for IFN- γ , IL-2, IL-4, IL-10, IL-13, TNF-alpha according to manufacturer's recommendations.

G. Preparation of colloidal size microbeads

- 25 Paramagnetic colloidal size beads can be purchased from Miltenyi Biotec (Auburn, CA; see, also U.S. Patent No. 6,417,011). As described in U.S. Patent No. 6,417,011, dextran coated paramagnetic colloidal size particles are prepared by mixing 10 g dextran T40 (Pharmacia, Uppsala Sweden), 1.5 g ferric chloride hexahydrate and 0.64 g ferrous chloride

-48-

tetrahydrate in 20 ml water and heating to 40° C. The solution is stirred and 20 ml 4 M NaOH is added dropwise with continued stirring. The resulting particle suspension is neutralized with acetic acid, centrifuged for 10 min at 2,000 x g, and filtered through a 0.22 μ m pore-size filter (Millex GV) to remove aggregates. Unbound dextran is removed by washing in a high gradient magnetic field by washing in columns of steel wool in a high gradient magnetic separation (HGMS) device at a strength of 0.6 Telsa. The particles are washed through the column. These particles can be further derivatized.

10

EXAMPLE 2

CD4 + cells purified from the peripheral blood of a cancer subject were divided in two groups: Group 1 were activated every 3 days for a period of 12 days and harvested on the 15th day. Group 2 were activated only once and harvested on the 15th day. Both groups of cells were then activated and incubated in the presence of IL-10 (100 pg/ml), IL-4 (50 pg/ml), IL-6 (100 pg/ml) and TGF-beta (100 pg/ml) to stimulate an immunosuppressive tumor environment. As a control, a portion of each group of cells was activated in the absence of immunosuppressive cytokines. The production of IFN- γ was measured after 24 hours and expressed as production per 10⁶ cells per 24 hours.

20

Group 1		Group 2	
No Cytokines	Cytokines	No Cytokines	Cytokines
2400 pg/ml	2200 pg/ml	200 pg/ml	26 pg/ml

25 These results indicate that cells produced by the methods provided herein are resistant to the immunosuppressive effects of cytokines that stimulate the intratumoral microenvironment. Cells subjected to a single activation produce 10-times less IFN- γ than the cells produced by the methods

-49-

herein. Further, IFN- γ production is inhibited by the presence of immunosuppressive cytokines in these cells.

EXAMPLE 3

Prior methods using immobilized anti-CD3/anti-CD28 stimulation have not been successful in expanding T-cells derived from cancer subjects without IL-2 supplementation. By eliminating the sources of TGF-beta from the initial cultures, cancer subject T-cells could be efficiently expanded without IL-2. This experiment was designed to determine the effect IL-2 addition had on the phenotype of the resulting cells using a prior single stimulation method compared with the repeated frequent stimulation method provided herein.

CD4+ cells from a cancer subject were purified by sorting on a flow cytometer. The resulting cells were cultured under the following conditions for 14 days: (Group 1) initial stimulation with anti-CD3/anti-CD28 with no IL-2; (Group 2) initial stimulation with anti-CD3/anti-CD28 with IL-2 (100 IU/ml); (Group 3) initial stimulation with anti-CD3/anti-CD28, no IL-2 and restimulation with anti-CD3/anti-CD28 every 3 days; and (Group 4) initial stimulation with anti-CD3/anti-CD28, IL-2 (100 IU/ml) and restimulation with anti-CD3/anti-CD28 every 3 days.

	Group 1	Group 2	Group 3	Group 4
CD4	99.56%	99.8%	91.34%	92.52%
CD45RA	29.02%	43.66%	10.84%	10.94%
CD45RO	42.62%	70.28%	73.64%	78.12%
CD62L	46.24%	52.76%	1.91%	.093%
CD25	64.02%	46.54%	87.89%	82.21%
CD44	99.94%	99.94%	92.91%	89.14%
Internal IFN +	24.65%	32.87%	86.83%	73.24%
Internal IL-4 +	15.7%	24.64%	7.42%	9.67%
IFN ELISA	85.6 pg/ml	105.9 pg/ml	8773 pg/ml	4401 pg/ml

-50-

	Group 1	Group 2	Group 3	Group 4
IL-4 ELISA	<26 pg/ml	<26 pg/ml	<26 pg/ml	<26 pg/ml
Fold Expansion	83	135	320	170

These results indicate that CD4 + cells derived from cancer subjects can
 5 be expanded with anti-CD3/anti-CD28 stimulation when the starting
 population is purged of platelets with or without the addition of IL-2. The
 addition of IL-2 also had little effect on the final phenotype of either
 group.

The repeated and frequent stimulation method enhances the ability
 10 of the cells to proliferate. These data also show that the repeat
 stimulation method results in a population of cells that has enhanced
 activation (CD25) and greatly enriched for IFN- γ production and IFN- γ
 internal staining. It is also relevant that the repeated and frequent
 stimulation method results in cells that have very low CD62L expression.
 15 These cells have a greater ability to infiltrate tumors and other sites of
 inflammation.

EXAMPLE 4

CD4 + , CD45RA + cells purified from the peripheral blood of a
 cancer subject were stimulated every 3 days with anti-CD3/anti-CD28.
 20 The cells were harvested on day 14 and analyzed for internal expression
 of IFN- γ and IL-4.

Day	% IFN- γ + internal stain	% IL-4 + internal stain
0	3.78	1.89
14	99.35	2.42

25 These data indicate that the method provided herein can cause naïve T-
 cells to differentiate into a highly pure population of Th1 cells.

-51-

EXAMPLE 5

CD4+ cells were purified from a normal donor. The cells in Group 1 were stimulated with anti-CD3/anti-CD28 only once. The cells in Group 2 were stimulated every 3 days. Both groups were cultured for 14 days.

5		Group 1	Group 2
	CD4	99.47	97.92
	CD45RA	10.29 %	18.23 %
	CD45RO	16.58 %	81.47 %
	CD62L	46.97 %	1.92 %
10	CD25	18.07 %	97.10 %
	CD44	99.52 %	99.08 %
	Internal IFN +	23.35 %	71.68 %
	Internal IL-4 +	6.14 %	4.08 %
	IFN ELISA	1651 pg/ml	6870 pg/ml
15	IL-4 ELISA	52 pg/ml	<26.1 pg/ml

These data indicate that the process results in an enhanced population of activated (CD25+), memory (CD45RO+) Th1 cells compared to single stimulation methods.

20

EXAMPLE 6

T-cells and T-cell subsets were purified from three different cancer subject PBMC by FACS. The blood was purified into four groups: (1) CD3+; (2) CD4+; (3) CD4+, CD45RO- and (4) CD4+, CD45RO+. The cells were stimulated every 3 days with immobilized anti-CD3/anti-CD28 mAb. The resulting cells were analyzed after 14 days of culture to assess their phenotypes.

-52-

Subject 1		CD3 +	CD4 +	CD4 +, CD45RO-	CD4 +, CD45RO +
5	CD4 +	70.94%	97.76%	99.52%	99.01%
	CD8 +	20.55%	0.45%	0.14%	1.72%
	CD45RA +	0.89%	4.01%	2.95%	1.62%
	CD45RO +	75.43%	87.68%	93.97%	96.80%
	CD62L +	2.49%	1.87%	9.72%	13.75%
10	CD25 +	78.98%	96.02%	92.97%	96.08%
	CD44 +	79.47%	99.20%	99.78%	99.42%
	Internal IFN +	64.87%	79.30%	70.05%	46.62%
	Internal IL-4 +	41.17%	13.94%	11.46%	4.82%
	IFN ELISA	1612 pg/ml	1092 pg/ml	4332 pg/ml	2664 pg/ml
15	IL-4 ELISA	<26 pg/ml	<26 pg/ml	<26 pg/ml	<26 pg/ml
	IL-13 ELISA	2810 pg/ml	2227 pg/ml	986 pg/ml	703 pg/ml
	TNF- α ELISA	8055 pg/ml	9000 pg/ml	384 pg/ml	359 pg/ml
	IL-10 ELISA	0 pg/ml	0 pg/ml	150 pg/ml	128 pg/ml
Subject 2		CD3 +	CD4 +	CD4 +, CD45RO-	CD4 +, CD45RO +
20	CD4 +	70.15%	98.35%	97.51%	96.09%
	CD8 +	23.53%	0.42%	0.19%	3.65%
	CD45RA +	0.93%	N.D.	2.02%	0.15%
	CD45RO +	72.03%	N.D.	96.47%	94.06%
	CD62L +	5.18%	N.D.	20.89%	13.22%
25	CD25 +	67.37%	N.D.	95.22%	93.85%
	CD44 +	68.05%	N.D.	96.24%	95.74%
	Internal IFN +	59.62%	86.09%	95.71%	54.78%

-53-

5	Internal IL-4 +	5.96%	11.68%	9.41%	3.41%
	IFN ELISA	20,868 pg/ml	25,514 pg/ml	13,100 pg/ml	1928 pg/ml
	IL-4 ELISA	< 26 pg/ml	< 26 pg/ml	< 26 pg/ml	< 26 pg/ml
	IL-13 ELISA	325 pg/ml	258 pg/ml	978 pg/ml	429 pg/ml
	TNF- α ELISA	1427 pg/ml	1025 pg/ml	2318 pg/ml	2318 pg/ml
	IL-10 ELISA	380 pg/ml	800 pg/ml	320 pg/ml	1000 pg/ml

Subject 3		CD4 +	CD4 +, CD45RO	CD4 +, CD45RO +
10	CD4 +	N.D.	98.56%	97.56%
	CD8 +	N.D.	0.07.%	1.75%
	CD45RA +	N.D.	5.17%	6.27%
	CD45RO +	N.D.	96.60%	97.36%
	CD62L	N.D.	1.30%	5.55%
15	CD25 +	N.D.	96.67%	94.55%
	CD44 +	N.D.	99.67%	97.60%
	Internal IFN +	N.D.	86.63%	73.45%
	Internal IL-4 +	N.D.	2.56%	4.95%
	IFN ELISA	N.D.	4138 pg/ml	2998 pg/ml
20	IL-4 ELISA	N.D.	< 26 pg/ml	< 26 pg/ml
	IL-13 ELISA	N.D.	4034 pg/ml	1746 pg/ml
	TNF-alpha ELISA	N.D.	2287 pg/ml	543 pg/ml
	IL-10 ELISA	N.D.	120 pg/ml	380 pg/ml

25

These data indicate that methods herein generate enhanced populations of activated Th1 memory cells from subject blood with or without purification of T-cell subsets.

-54-

EXAMPLE 7

The following data demonstrate the consistency in compositions of resulting cells produced by the methods provided herein from samples from eight different cancer subjects and 8 different normal subjects.

5	Cancer Donors: Initial phenotype			Harvest phenotype (day 14)					
		Total CD4	CD4/CD45RO	CD4	CD4/CD45RO	CD4/62L low	CD4/CD25	CD4/CD44	%IFN- γ /IL-4
10	1	4.6%	1.9%	99%	96.6%	98.7	96.6	99.67	86.6/2.5
	2	10%	4.6%	98.2	96.47	79.1%	95.2	96.2	86.1/11.6
	3	6.8%	4.1%	96	94.8	80.1	86.7	93.7	84.9/5.6
	4	9.5	8.0	99	98.1	98.5	93.7	99.1	75.4/4.7
	5	47.3	25.6	92	87.6	98.1	96.2	99.7	79.3/13.9
	6	14.1	6.9	99	89.2	97.5	98.6	99.6	77.7/16.2
	7	31	12	99	93.3	94.1	87.2	98.2	92.6/10.3
15	8	7.2	6.7	95	93.2	71.2	97.6	97.8	94.3/6.4

20	Normal Donors: Initial phenotype			Harvest phenotype (day 14)					
		Total CD4	CD4/CD45RO	CD4	CD4/CD45RO	CD4/62L (-)	CD4/CD25	CD4/CD44	%IFN- γ /IL-4
	9	33%	23%	94.6	94.5	72.1	87.23	99.9	82.1/0.9
	10	35.8	19.3	98.2	98.2	96.4	07.47	99.8	97.1/3.7
	11	27.5	12.1	99.1	99.4	91.2	98.6	99.4	71.9/5.1
	12	6.4	3.4	97	89.7	98.3	92.98	93.7	73.8/13.3
	13	23	15	99	88.1	99.7	97.7	98.4	90.2/12.2

-55-

Normal Donors: Initial phenotype			Harvest phenotype (day 14)					
14	35	19	99.9	99.9	70.1	98.1	91.4	86.4/7.2
15	33	18	99.9	99.9	82.3	93.8	92.9	80.3/11.2
16	29	18	95	94.5	85.5	90.1	94.6	94.6/3.4

- 5 These data show that consistent compositions are produced from various starting populations.

EXAMPLE 8

- The following data show a time course of the production of IFN- γ , IL-4 and IL-2 (ELISA; pg/ml) as a function of days in culture for various samples from three different cancer subjects using the methods herein.
- 10 Th1 differentiation correlates with IFN- γ production for each subject.

Subject 1	IFN- γ	IL-4	IL-2
day 1	99.1	26.1	1029
15 day 2	87.3	26.1	1651.7
day 3	120.3	67.5	6151.87
day 4	174.6	58.3	1116.8
day 5	164.1	28.5	186.1
day 6	187.2	26	101.2
20 day 7	761.4	27.2	319
day 8	1672.3	25	50
day 9	1521.2	25	50
day 10	2500	25	50
day 12	2500	25	50
25 harvest	1003	25	150

-56-

	Subject 2	IFN- γ	IL-4	IL-2
	day 1	45	15	366
	day 2	60	15	3000
5	day 3	900	78	7500
	day 4	3900	108	7500
	day 5	4500	15	5500
	day 6	6300	15	200
	day 7	6900	15	3210
10	day 8	6900	15	783
	day 9	6900	15	170
	day 10	7200	15	636
	day 11	7200	15	1300
	day 12	7200	15	1800
15	harvest	7200	00	1585

	Subject 3	IFN- γ	IL-4	IL-2
	day 4	120.1	92.6	152.1
	day 5	154.6	129.9	159.1
20	day 6	193.8	76.9	150
	day 7	290.8	28.14	150
	day 9	910.9	25	150
	day 12	7387	25	150
25	harvest	7000	25	150

These data also demonstrate that IFN- γ , and thus, Th1 differentiation, peaks between about day 9 to day 12.

-57-

EXAMPLE 9

The following example demonstrates that the method provided consistently produce populations of highly pure, activated, polyclonal memory Th1 cells from a subject blood sample in the absence of any
 5 exogenous growth or differentiation factors,

Sixty-four blood samples were obtained. Of these 31 were from patients with metastatic cancer and 33 were from normal donors. The samples included 5 from patients with metastatic breast cancer, 4 from patients with NSCLC (lung cancer), 4 from patients with melanoma, 3
 10 from patients with colon cancer, 2 from patients with prostate cancer, 2 from patients with non-Hodgkin's lymphoma, 2 from patients with pancreatic cancer, 2 from patients with liver cancer, 1 from a patient with cervical cancer, 1 from a patient with ovarian cancer, 1 from a patient with renal cell carcinoma, 1 from a patient with esophageal cancer, 1
 15 from a patient with head and neck cancer, 1 from a patient with brain cancer and 1 from a patient with stomach cancer.

Mononuclear cells were isolated from 50 ml peripheral blood samples by density gradient centrifugation. CD4+ cells were purified by positive selection with biotinylated anti-CD4 mAB and anti-biotin
 20 microbeads (Miltenyi) in a magnetic field. The CD4+ cells were incubated for 14 days in serum-free medium with no supplements. Cells were stimulated every 3 days with anti-CD3/anti-CD28 monoclonal antibody conjugated 4.5 micron paramagnetic beads. The resulting populations of cells were as follows:

25	Description of phenotype of cells	Cancer donors (n=31)	Normal donors (n=33)
	%CD4+	97.70 ± 2.97	97.14 ± 5.35
	%CD4+/CD45RO+	94.17 ± 10.68	88.70 ± 21.88
	%CD4+/CD62low	88.99 ± 13.16	86.83 ± 14.69

-58-

5	%CD4 + /CD25 +	95.72 \pm 6.41	93.06 \pm 16.54
	%CD4 + /CD44 +	99.36 \pm 0.80	98.97 \pm 2.30
	%CD4 + /CD40L +	40.90 \pm 14.26	61.38 \pm 23.32
	ICC IFN- γ	74.77 \pm 14.14	61.12 \pm 26.32
	ICC IL-4	13.46 \pm 15.53	13.79 \pm 13.27

* ICC indicates internal cytokine staining;

10 ** Percentage of cells staining positive for the phenotypic marker by standard flow cytometry methods, expressed as the mean \pm standard error.

These results show that the methods produced population of cells that do not vary significantly from patient and between cancer patients and normal donors as is observed using other methods. This indicates that the method reproducibly produces a consistent end product that will not vary from batch-to-batch.

EXAMPLE 10

Preparation of anti-CD3 and anti-CD28 monoclonal antibody colloidal paramagnetic beads

20 Human anti-CD3 and anti-CD28 mouse monoclonal antibodies are immobilized on Miltenyi Goat-Anti-Mouse (GAM) micro-beads for Th1 cell expansion. The beads are used for activation of primed CD4+ T cells (CD4+ T cells activated using Human anti-CD3 and anti-CD28 immobilized on Dynal beads). Advantages of using these beads include, 25 for example: 1) The Miltenyi beads are micro particles that remain in colloidal suspension, as a result these beads do not settle at the bottom of the flask in bioreactor; 2) Miltenyi micro-particles following binding to CD4 T cells will be internalized or shed, as a result the activation signal through CD3 and CD28 will be transient and not continuous; and 3) the 30 need to de bead the product prior to infusion in patients is eliminated.

A. Materials:

Goat anti-Mouse IgG Miltenyi Microbeads

-59-

Dulbecco's Phosphate Buffered Saline (dPBS)

General Buffer (dPBS with 1% HSA)

OKT3 human anti-CD3 monoclonal Antibody, 1 mg/ml (Ortho)

5 CD28 ASR, human anti-CD28 Bulk monoclonal Antibody, 1 mg/ml
(BD)

MS or LS column for MiniMACS or OctoMACS (Miltenyi order #
130-042-201 or 130-042-401)

MiniMACS (Miltenyi order # 130 042 302) or MidiMACS unit
(Miltenyi order #130 042 102)

10 Sample CD3/CD28 Antibody Solution for Quality Control

Sample CD3/CD28 Expansion Beads for Quality Control

Miltenyi CD3/CD28 T-Cell Expansion Beads

B. Preparation

15 To prepare the beads, human anti-CD3 and anti-CD28 were mixed
at ratio of 1:1 and added to the solution of beads. The mixture of beads
and antibodies was incubated room temperature. The beads were washed
on a Miltenyi MS column 10 times to remove unbound antibodies and
eluted from the column using X-vivo15.

To prepare the volume of beads to be conjugated is selected.

20 Each 2 mL of GAM Miltenyi beads results in about 2 mL of anti-CD3/anti-
CD28 beads. Twenty μ L of anti-CD3/anti-CD28 beads were required to
stimulate $\leq 10^7$ total cells. The colloidal solution of GAM Miltenyi beads
was gently vortexed to re-suspend the beads, which were then
transferred to a 12 x 75 polypropylene tube for coupling the antibodies.

25 To prepare a CD3/CD28 antibody solution, CD3 and CD28
antibodies were mixed together in equal amounts to produce a
homogeneous solution. For each 500 μ l of GAM beads 100 μ g each of
anti-CD3 and anti-CD28 antibody solution was used. The solution was
produced by mixing equal amounts of anti-CD3 and anti-CD28 antibodies.

-60-

For conjugation of the antibodies to the beads, 200 μ l of anti-CD3/anti-CD28 solution was added for every 500 μ l of GAM Miltenyi beads and the resulting mixture is gently vortexed. The antibody-bead solution tube was placed on spindle rotors for 60 minutes at room temperature.

To remove the unbound antibody, an MS column was assembled in the magnetic field of an OctoMACS separator (Miltenyi Magnet). A collection tube was placed under the column. 500 μ l of degassed PBS buffer was placed on top of the column and run through to pre-equilibrate. The bead-antibody solution was loaded onto the pre-equilibrated column. Antibody-bead solution was run through, and unbound antibody in the effluent was collected. The column was washed with 10 x 500 μ L General Buffer (dPBS with 1% HSA) and total effluent collected as negative fraction (contains unbound antibody). 500 μ l of X-Vivo15 was applied to the column and the beads pushed out and stored in a sterile 50 mL conical centrifuge tube at 4° C

EXAMPLE 11

Th1 Cell Preparation using antibodies immobilized on nanobeads for re-stimulation

A. Preparation of the Th1 cells

As in the above Examples, leukocytes (~5000 ml) were obtained from Donor/Patients by leukapheresis. The leukapheresis product was further purified using magnetic separation techniques, described above, to isolate that CD4 cell fraction (>80% pure). The CD4 cell fraction and anti-CD3/anti-CD28 immobilized Dynal beads were incubated together for 3 days. Briefly, approximately 25×10^6 purified CD4+ cells were placed in a sterile 12 x 75 culture tube with cap. The cells were centrifuged and the supernatant discarded. The cells were resuspended in 2.5 mL X-VIVO 15 Medium (10×10^6 cells per mL).

-61-

1875 μ L of CD3/CD28 coated sheep anti mouse IgG (SAM) Dynabeads (4×10^7 beads/mL at a 3:1 ratio of beads to cells) were dispensed into a 50 mL conical centrifuge tube, which was placed into the MPC Magnet and rocked gently 5 times to expose all of the liquid to the magnet. At the end of 5 minutes, with the tube on the magnet, the supernatant X-Vivo 15 medium was removed. The tube was then removed from the magnetic field. The beads were gently disturbed by tapping the tube.

The purified CD4+ cells gently mixed with the bead pellet by tapping. The tube was placed on ice for 20 minutes and vortexed gently every 5 minutes during this incubation. 22.5 mL of pre-warmed X-Vivo 15 was added to the 2.5 mL bead/cell mixture for a final concentration of 1×10^6 cells/mL. These cells were inoculated into a culture bag (LifeCell). The bag was placed in a 37°C incubator at 5% CO₂ and 100% humidity. The Dynal Beads were removed by magnetic separation resulting in a cell culture mixture.

B. Restimulation and expansion of Th1 Cells in Bags

The cell culture mixture is re-stimulated with anti-CD3/anti-CD28 immobilized on GAM Miltenyi microbeads (Miltenyi Biotec, Auburn CA), prepared as described in EXAMPLE 10. At day 3 (72 hours post initiation, the contents of the bag were gently but thoroughly mixed, and then transferred to a 50 mL conical centrifuged tube, which was placed into the MPC Magnet for 5 minutes. The supernatant was removed and into a fresh 50 mL conical centrifuge tube.

About 5.0 mL of the well-mixed cell suspension was transferred into each of 2 tubes for analyses. The tube containing the bulk of the cell suspension was centrifuged at 1200 rpm for 5 minutes, and the supernatant was transferred into another sterile 50 mL conical centrifuge

-62-

tube, centrifuged and resuspended in conditioned medium at a cell density of 100×10^6 cells/mL (WBC count from Sysmex x volume of medium x % viability)/100 = mL of conditioned medium to add) and placed on ice.

- 20 μ L of anti-CD3/anti-CD28-GAM-Miltenyi microbeads per 10×10^6 cells was added, mixed well, incubated on ice for 20 minutes, vortexing gently every 5 minutes during the incubation.

- When incubation is complete the density is adjusted by addition of a 25:75 (v/v) mixture of conditioned medium and fresh X-Vivo 15 to 1×10^6 cells/mL. These cells are inoculated into a new culture bag and incubated. Each day of the incubation, a portion of the working supernate is exchanged for fresh medium to replenish nutrients and remove waste products.

- On day 6 and day 9 of the culture, the cell culture mixture is re-stimulated with anti-CD3/Anti-CD28 immobilized on GAM Miltenyi Micro Beads. 20 μ L of anti-CD3/anti-CD28-GAM-Miltenyi microbeads was added per 10×10^6 cells that had been resuspended at a density of 100×10^6 / mL. The tube containing the cell/bead suspension was placed into an ice bath for twenty minutes and mixed gently every five minutes during the cold incubation, the cells bead mixture is transferred to a culture bag, which was placed in the incubator. On day 13, the cells were harvested.

C. Results

The resulting cells had the following properties, which indicate that they are polyclonal Th1 cells:

- 25 A. Purity $\sim 99\%$ CD4+ and CD3+.
- B. Viability $> 90\%$
- C. Produce a large amount of INF-gamma cytokine (up to about 10 ng per million cells)
- D. Do not produce detectible IL-4

-63-

- E. Do not produce detectible TGF-beta
 - F. Do not produce detectible IL-10.
 - G. Do not have detectible CTLA-4 on cell surface.
 - H. At gene expression level these cells exhibit:
 - 5 1. detectible expression of INF-gamma, IL-2, IL-15, IL-18, TNF-alpha, TNF-beta.
 - 2. undetectible IL-4, IL-10, IL-5, IL-12P35, IL-12P40, IL-1beta, IL-150 alpha, IL-6 expression.
- 10 Since modifications will be apparent to those of skill in this art, it is intended that this invention be limited only by the scope of the appended claims.

-64-

CLAIMS:

1. A method for producing a highly pure population of Th1 cells, comprising:
 - purifying T-cells from the source material; and
 - 5 activating the T-cells a plurality of times, whereby a highly pure population of Th1 cells is produced.
2. The method of claim 1, wherein:
 - the source material is collected from a subject;
 - the T-cells are activated at least minimum of 3 times at 2-4
 - 10 day intervals to produce a highly pure population of polyclonal Th1 memory cells.
3. The method of claim 1 or claim 2, wherein the T-cells are activated 3 to 5 times at 2-4 day intervals.
4. The method of any of claims 1-3, wherein the T-cells are
- 15 purified CD4+ cells.
5. The method of claim 4, wherein the CD4+ cells are purified by positive selection.
6. The method of claim 5 wherein the CD4+ cells are purged of CD45RO+ cells.
- 20 7. The method of claim any of claims 1-6, wherein the source material is purged of platelets.
8. The method of claim 6, wherein the source material is purged of platelets.
9. The method of claim 1 or claim 2, wherein the source
- 25 material is purged of monocytes.
10. The method of claim 7, wherein the source material is purged of monocytes.

-65-

11. The method of claim 1 or claim 2, wherein the activation of T-cells is effected by contacting the cells with anti-CD3 and anti-CD28 monoclonal antibodies (mAbs).

12. The method of claim 10, wherein the anti-CD3 and anti-CD28 mAbs are immobilized.

13. The method of claim 12, wherein the mAbs are immobilized on particulate supports.

14. The method of claim 12, wherein particulate supports are immunomagnetic beads.

15. The method of claim 12, wherein the Mabs are immobilized on colloidal size paramagnetic beads during at least the last activation step.

16. The method of claim 11, wherein the mAbs are immobilized on colloidal size paramagnetic beads during at least two activation steps.

17. The method of claim 11, wherein the beads are initially administered to the purified T-cells at a 3:1 particulate:cell ratio and subsequently at a 1:1 particulate:cell ratio.

18. The method of claim 1 or claim 2, wherein the source material comprises mononuclear cells.

19. The method of any of claims 2-18, wherein the subject is a human cancer patient.

20. The method of claim 19, wherein the cancer is selected from the group consisting of liver, kidney, breast, prostate, melanoma, colon, lymphoma, lung, pancreatic, ovarian, esophageal, head and neck, brain, uterine and stomach cancer.

21. The method of claim 1 or claim 2, wherein the Th1 cells are activated.

22. The method of claim 21, wherein the population comprises at least 10^9 Th1 cells.

-66-

23. The method of claim 22, wherein the 10^9 cells are in a volume of about 1 liter or less.

24. A method comprising:

(a) collecting a sample of mononuclear cells from a subject with a
5 disease characterized by either an excess of Th2 cytokine activity or low Th1 cytokine activity; and

(b) processing the mononuclear cells *ex vivo* without the use of any exogenous cytokines to produce an expanded population of highly pure Th1 memory cells.

10 25. The method of claim 24, further comprising:

(c) infusing the Th1 memory cells into a subject, thereby altering the Th1/Th2 cell balance of the subject.

26. The method of claim 24 or claim 25, wherein the subject is the donor.

15 27. The method of any of claims 24-26, wherein the expanded population comprises at least 10^9 Th1 cells.

28. The method of claim 27, wherein the 10^9 cells are in a volume of about 1 liter or less.

29. The method of any of claims 24-28, wherein the subject is a
20 human cancer patient.

30. The method of any of claims 24-29, wherein the disease is selected from the group consisting of diseases characterized by suppression of the cellular immune response or by over-expression of the humoral immune response.

25 31. The method of any of claims 24-30, wherein the disease is selected from the group consisting of cancer, infectious diseases, autoimmune and allergic diseases.

-67-

32. The method of any of claims 24-31, wherein processing is effected by a method, comprising: purifying CD3+ cells from the mononuclear cells.

5 33. The method of any of claims 24-31, wherein processing is effected by a method, comprising purifying CD3+ CD4+ cells from the mononuclear cells.

34. The method of any of claims 24-31, wherein processing is effected by a method, comprising purifying CD3+, CD4+, CD45RA+ cells from the mononuclear cells.

10 35. The method of any of claims 24-31, wherein processing is effected by a method, comprising:

(i) reducing the platelet concentration in the sample;

(ii) purging the CD45RO+ cells from the population of mononuclear cells;

15 (iii) purifying by positive selection a population of CD4+, CD45RA+ cells;

(iv) activating the resulting CD4+ cells in the absence of exogenous cytokines with immobilized anti-CD3/anti-CD28 mAbs;

20 (v) periodically restimulating with immobilized anti-CD3/anti-CD28 mAbs.

36. The method any of claims 24-35, wherein the cells are restimulated every 2-3 days with immobilized anti-CD3/anti-CD28 mAb for a total of 10-14 days.

37. The method of claim 36, further comprising:

25 (c) infusing the Th1 memory cells into a subject, thereby altering the Th1/Th2 cell balance of the subject.

38. The method of claim 37, wherein the subject is the donor.

39. The method of any of claims 24-37, wherein the expanded population comprises at least 10^9 Th1 cells.

-68-

40. The method of claim 39, wherein the 10^9 cells are in a volume of about 1 liter or less.

41. The method of any of claims 24-31, wherein processing is effected by a method, comprising:

- 5 (i) reducing the number of platelets in the sample;
- (ii) purging macrophages from the sample;
- (iii) purging the CD45RO + cells from the sample
- (iv) purifying by positive selection a population of CD4 + ,
CD45RA + cells;
- 10 (v) activating the CD4+ cells in the absence of exogenous cytokines with immobilized anti-CD3/anti-CD28 mAb; and
- (vi) periodically restimulating with immobilized anti-CD3/anti-CD28 mAb.

42. The method of claim 41, wherein the cells are restimulated
15 every 2-3 days with immobilized anti-CD3/anti-CD28 mAb for a total of 10-14 days.

43. The method of claim 41 or claim 42, further comprising:

(c) infusing the Th1 memory cells into a subject, thereby altering the Th1/Th2 cell balance of the subject.

20 44. The method of any of claims 41-43, wherein the subject is the donor.

45. The method of any of claims 41-44, wherein the expanded population comprises at least 10^9 Th1 cells.

46. The method of claim 45, wherein the 10^9 cells are in a
25 volume of about 1 liter or less.

47. The method of any of claims 24-41, wherein the Th1 cells are activated.

48. A composition, comprising at least about 90% activated Th1 cells.

-69-

49. The composition of claim 48, comprising at least about 95% Th1 cells.

50. The composition of claim 48, wherein the cells are polyclonal memory Th1 cells.

5

51. A composition of Th1 cells produced by the method of any of claims 1-47.

52. A method of treating a disease, comprising:

10 infusing a composition of any of claims 48-51 into a subject with symptoms of a disease, wherein:

the disease is characterized by suppression of the cellular immune response, by over-expression of the humoral immune response, excess Th2 activity or a lack or decreased Th1 activity.

15 53. The method of claim 52, wherein the disease is selected from the group consisting of cancer, infectious diseases and allergic diseases.

54. A process for producing compositions comprising at least 70% Th1 cells, comprising:

20 (a) collecting a sample of mononuclear cells from a subject with a disease characterized by either an excess of Th2 cytokine activity or lack of Th1 cytokine activity;

(b) removing platelets from the sample;

(c) removing macrophages from the sample;

25 (c) depleting CD45RO+ cells from the sample by negative selection;

(d) selecting the CD4+ cells by positive selection; and

(e) expanding and differentiating the selected CD4+ cells by repeatedly stimulating the selected CD4+ cells with immobilized anti-CD3/anti-CD28 antibodies.

-70-

55. The method of claim 54, wherein the polyclonal Th1 memory cells are activated.

56. The method of claim 54 or claim 55, wherein the disease is selected from the group consisting of diseases characterized by excess
5 Th2 activity or a lack or decreased Th1 activity.

57. A process for producing compositions that have an enhanced population of activated polyclonal Th1 memory cells, comprising:

- (a) collecting a sample of mononuclear cells from a subject;
- (b) expanding and differentiating the mononuclear cells by
10 repeatedly activating T-cells in the mononuclear cell sample in the absence of exogenous growth or differentiation factors, thereby producing a highly pure population of activated polyclonal Th1 memory cells.

58. The method of claim 57, wherein prior to expanding an
15 differentiating the T-cells are purified from the mononuclear cells.

59. The method of claim 58, wherein the T-cells purified from the mononuclear cells are selected from the group consisting of CD3+ cells, CD4+ cells, CD4+, CD45RA+ cells and CD4+, CD45RO+ cells.

60. A method for expanding T-cells from cancer patients without
20 the use of exogenous cytokines, comprising:

- (a) collecting a mononuclear cell sample from a cancer patient;
- (b) purging platelets from the mononuclear cells; and
- (c) activating the cells with immobilized anti-CD3/anti-CD28 mAbs,
wherein all steps are performed in the absence of exogenous cytokines.

25 61. The method of claim 60, wherein the disease is cancer.

-71-

62. The method of claim 61, wherein the disease is selected from the group consisting of liver, kidney, breast, prostate, melanoma, colon, lymphoma, lung, pancreatic, ovarian, esophageal, head and neck, brain, uterine and stomach cancer.

5 63. A composition of cells, comprising at least about 10^9 cells, wherein at least about 70% of the cells are polyclonal Th1 memory cells.

64. The composition of claim 63, wherein the Th1 cells are activated.

65. The composition of claim 63 or claim 63 that is in a volume
10 of about a liter or less.

66. A composition of activated polyclonal Th1 memory cells produced by the method of claim 57.

67. A combination, comprising a composition of claim 51 and an immunizing antigen.

15 68. A combination, comprising a composition of claim 47 and an immunizing antigen.

69. The method of claim 54, wherein:
at least 10^{10} cells are produced; and
at least 70% are positive for internal interferon- γ .

20 70. The method of claim 69, wherein the cells are in a volume of about 1 liter or less.

71. The method of claim 69, wherein the density of cells is at least 10^{11} cells/liter.

72. A highly pure population of Th1 cells, wherein positive for
25 internal interferon- γ and the cells are at a density of at least 10^{10} cells/liter.

73. The cells of claim 72, wherein the density of cells is at least 10^{11} cells/liter.

-72-

74. The method of claim 35, wherein the mAbs are immobilized on particulate supports.

75. The method of claim 74, wherein particulate supports are immunomagnetic beads.

5 76. The method of claim 74, wherein particulate supports are colloidal sized paramagnetic beads.

77. The method of claim 36, wherein the mAbs are immobilized on colloidal size paramagnetic beads.

10 78. The method of claim 60, wherein the mAbs are immobilized on particulate supports.

79. The method of claim 78, wherein particulate supports are immunomagnetic beads.

80. The method of claim 78, wherein the particulate supports are colloidal size paramagnetic beads.

15 81. A composition, comprising at least 70% polyclonal memory Th1 cells.

82. The composition of claim 81, comprising at least 10^9 Th1 memory cells.


20 83. The composition of claim 82, wherein the Th1 cells are CD3+, CD4+, CD45RO+, CD62L-, CD44+ and CD25+.

84. The composition of claim 82 that has density of cells greater than about 10^6 cells per ml or 10^7 cells per mol or 10^8 cells per ml.

INTERNATIONAL SEARCH REPORT

International application No. ,

PCT/US02/29591

A. CLASSIFICATION OF SUBJECT MATTER IPC(7) : A01N 1/02, 63/00, C12N 5/08 US CL : 435/2, 372, 372.3, 375, 377; 424/93.71 According to International Patent Classification (IPC) or to both national classification and IPC												
B. FIELDS SEARCHED Minimum documentation searched (classification system followed by classification symbols) U.S. : 435/2, 372, 372.3, 375, 377; 424/93.71 Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) Please See Continuation Sheet												
C. DOCUMENTS CONSIDERED TO BE RELEVANT												
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.										
Y	WO 97/05239 A1 (CELLTHERAPY, INC) 13 February 1997, see entire document.	1-3,9,11,16-18,21-26,48-50,54-64,66,69-73,78-84										
Y	Database BIOSIS on DIALOG, No. 1186664. SASAMA et al. "Effect of Il-4, IFN-gamma and Il-12 on Cytokine Production from Human CD45RA and CD45RO CD4 T Cell Precursors". International Archives of Allergy and Immunology. December 1998, Vol. 117. pages p255-262, abstract, see entire document.	1-3,9,11,16-18,21-26,48-50,54-64,66,69-73,78-84										
Y	Database SCISEARCH on DIALOG, No. 055535566. HELBERT et al. "HIV Infection of CD45RA(+) and CD45RO(+) T Cells". Clinical and Experimental Immunology. February 1997, Vol. 107. No. 2, pages 300-305, abstract, entire document.	1-3,9,11,16-18,21-26,48-50,54-64,66,69-73,78-84										
<input type="checkbox"/> Further documents are listed in the continuation of Box C. <input type="checkbox"/> See patent family annex.												
* Special categories of cited documents: <table border="0"> <tr> <td>"A" document defining the general state of the art which is not considered to be of particular relevance</td> <td>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</td> </tr> <tr> <td>"E" earlier application or patent published on or after the international filing date</td> <td>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone</td> </tr> <tr> <td>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</td> <td>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art</td> </tr> <tr> <td>"O" document referring to an oral disclosure, use, exhibition or other means</td> <td>"&" document member of the same patent family</td> </tr> <tr> <td>"P" document published prior to the international filing date but later than the priority date claimed</td> <td></td> </tr> </table>			"A" document defining the general state of the art which is not considered to be of particular relevance	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention	"E" earlier application or patent published on or after the international filing date	"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone	"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art	"O" document referring to an oral disclosure, use, exhibition or other means	"&" document member of the same patent family	"P" document published prior to the international filing date but later than the priority date claimed	
"A" document defining the general state of the art which is not considered to be of particular relevance	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention											
"E" earlier application or patent published on or after the international filing date	"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone											
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art											
"O" document referring to an oral disclosure, use, exhibition or other means	"&" document member of the same patent family											
"P" document published prior to the international filing date but later than the priority date claimed												
Date of the actual completion of the international search 07 December 2002 (07.12.2002)		Date of mailing of the international search report 13 JAN 2003										
Name and mailing address of the ISA/US Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231 Facsimile No. (703)305-3230		Authorized officer  Ron Schwadron, Ph.D. Telephone No. 703 3080196										

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US02/29591

Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)

This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claim Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☐ Claim Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☒ Claim Nos.: 4-8, 10, 12-15, 19, 20, 27-47, 51-53, 65, 67, 68, 74-77
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

☐
☐

The additional search fees were accompanied by the applicant's protest.

No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

PCT/US02/29591

Continuation of B. FIELDS SEARCHED Item 3:

WEST 2.1, MEDICINE/BIOTECH (compendium databases on DIALOG) search terms: inventor name, Th1_Th2, cd4, cd3, cd28,